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ABSTRACT 
 
In the ambulatory assessment of women with abnormal uterine bleeding, the main aim 
is to reach a diagnosis and thereby allow appropriate treatment. Excluding 
endometrial pathology, particularly carcinoma and hyperplasia, is of paramount 
importance. However there is no consensus as to which set of investigations should be 
used (hysteroscopy, ultrasonography and endometrial sampling). There is a lack of 
good quality research evidence on the accuracy of the various diagnostic tests in 
predicting endometrial lesions. This dearth of relevant evidence prompted the 
research presented in this thesis to address and answer the following research 
questions:  
• What is the accuracy of outpatient miniature hysteroscopy / ultrasonography in the 
identification of premalignant and malignant endometrial lesions?  
• What is the relative significance of hysteroscopic and ultrasonographic evidence 
of endometrial atrophy in relation to an insufficient sample on outpatient 
endometrial biopsy? 
• What is the risk of premalignant and malignant pathology among endometrial 
polyps? What is the significance of various risk factors associated with 
endometrial polyps? 
• What is the feasibility of multivariable analysis to evaluate combinations of 
diagnostic tests in the diagnosis of endometrial disease? 
 
Findings and Conclusions 
Positive hhysteroscopy is accurate in ruling in endometrial cancer and hyperplasia 
(the LR was 51.1 (95% CI 7.9-326.9). Using endometrial thickness >4mm at 
ultrasound scan, ultrasound is accurate in ruling out endometrial cancer and 
hyperplasia (the LR was 0.14 (95%CI 0.02-0.64).   
 
Insufficient sample on endometrial biopsy was more common among cases with 
hysteroscopic finding of endometrial atrophy (adjusted OR= 4.79, 95% CI 1.05-21.91, 
p=0.04) and less common among cases with sonographic endometrial thickness above 
5mm (adjusted OR=0.19, 95% CI 0.07-0.53, p=0.001). Therefore insufficient sample 
may be considered a substitute to absence of pathology provided the hysteroscopic 
and sonographic endometrial assessment is consistent with endometrial atrophy.   
 
Hyperplasia was more frequent in endometrial specimens with polyps than in those 
without (9.7% vs 4.8%, OR=2.1, 95% CI 0.85-5.2), but the rate of carcinoma in the 
two groups was not statistically different (4.8% vs 3.2%, OR=1.5, 95% CI 0.46-5.0). 
Tamoxifen treatment was associated with endometrial polyps (adjusted OR= 8.16, 
95% CI 2.01-33.2, p=0.003) but hormone replacement therapy was not (adjusted 
OR=1.35, 95% CI 0.65 – 2.81, p=0.42). 
 
The true clinical value of a test lies in the added information over and above what was 
already known from the history and examination. It is feasible to develop a stepwise 
multivariable analytic approach to explore the added value of tests (hysteroscopy or 
ultrasonography) over and above history when predicting endometrial hyperplasia or 
cancer. This analytic strategy needs to be applied in larger datasets to draw clinical 
conclusions. 
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EXECUTIVE ABSTRACT 
 
Background  
In ambulatory assessment of women with abnormal uterine bleeding, the main aim is to exclude 
endometrial pathology, particularly carcinoma and hyperplasia. However there is no consensus as to 
which set of investigations should be used. While some clinicians resort to ultrasound imaging 
techniques as well as tissue sampling, others advocate endoscopic examination. There is a lack of 
good quality research evidence on the accuracy of the various diagnostic tests in predicting 
endometrial lesions. This dearth of relevant evidence prompted the research presented in this thesis.  
 
Objectives 
This thesis addresses the following research questions:  
1. What is the accuracy of outpatient miniature hysteroscopy in the identification of 
premalignant and malignant endometrial lesions?  
2. What is the accuracy of ultrasound scan in the identification of premalignant and malignant 
endometrial lesions? 
3. What is the relative significance of hysteroscopic and ultrasonographic evidence of 
endometrial atrophy in relation to insufficient sample on outpatient endometrial biopsy? 
4. What is the risk of premalignant and malignant pathology among endometrial polyps? 
5. What is the significance of various risk factors associated with endometrial polyps? 
6. What is the feasibility of multivariable analysis to evaluate combinations of diagnostic tests 
in the diagnosis of endometrial disease? 
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Methods  
A prospective cohort study was performed on 248 patients evaluated for abnormal uterine bleeding 
in the One-stop clinic at Birmingham Women’s Hospital from November 1996 to December 1997. 
Outpatient hysteroscopy, ultrasonography and endometrial sampling were performed. Histological 
diagnosis was used as a “gold standard” for cancer and hyperplasia. The histological nature of the 
polyp was confirmed in all patients by performing inpatient polypectomy.  
  
For each question, the methodology was as follows:  
1. For the diagnostic value of hysteroscopy, a test accuracy study was carried out where 
likelihood ratios (LRs) and post-test probabilities were computed along with confidence 
intervals (CI).  
2. For the diagnostic value of ultrasonography, a test accuracy study was carried out where 
LRs and post-test probabilities were computed along with confidence intervals.  
3. Multivariable logistic regression modelling was used to evaluate the independent association 
of hysteroscopic findings and sonographic endometrial thickness with insufficient outpatient 
endometrial sampling controlling for the effects of age and menopausal status. 
4. To determine the magnitude of malignant potential among polyps, the odds for pathological 
findings in polyps (cases) were statistically compared with the odds amongst non-polypoidal 
specimens (controls). 
5. Multivariable logistic regression modelling was used to evaluate the effects of age, parity, 
menopausal status, hormone replacement therapy and tamoxifen treatment on the occurrence 
of polyps.  
6. Multivariable logistic regression models were built in a stepwise fashion, to test whether 
ultrasonography and/or hysteroscopy increased the prediction of serious endometrial 
pathology above that predicted from clinical history alone. The diagnostic accuracy of the 
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models was determined by the area under the receiver operating characteristic curve. 
 
Findings  
1. For normal findings at hysteroscopy the LR was 0.7 (95% CI 0.5-0.9). With definitely 
abnormal findings at hysteroscopy, the LR was 51.1 (95% CI 7.9-326.9) for predicting 
premalignant and malignant endometrial lesions. 
2. For endometrial thickness <4mm at ultrasound scan, the LR was 0.14 (95%CI 0.02-0.64). It 
was 0.94 (95%CI 0.37-1.99) for endometrial thickness 4.1-9.0mm, and 3.3 (95%CI 1.73-
5.73) for endometrial thickness >9.0mm for predicting premalignant and malignant 
endometrial lesions. 
3. Insufficient sample on endometrial biopsy was more common among cases with 
hysteroscopic finding of endometrial atrophy (adjusted OR= 4.79, 95% CI 1.05-21.91, 
p=0.04) and less common among cases with sonographic endometrial thickness above 5mm 
(adjusted OR= 0.19, 95% CI 0.07-0.53, p=0.001).  
4. Hyperplasia was more frequent in endometrial specimens with polyps than in those without 
(9.7% vs 4.8%, OR=2.1, 95% CI 0.85-5.2), but the rate of carcinoma in the two groups was 
not statistically different (4.8% vs 3.2%, OR=1.5, 95% CI 0.46-5.0). 
5. Tamoxifen treatment was associated with endometrial polyps (adjusted OR= 11.21, 95% CI 
2.70 – 46.46, p=0.0009) but hormone replacement therapy was not (adjusted OR= 1.48, 95% 
CI 0.68 - 3.20, p=0.32). 
6. The area under the receiver operating characteristic curve for the model including historical 
features alone was 0.78. When hysteroscopy and ultrasonography were added to the model, 
the ROC area increased to 0.81 (p=0.008 for improvement) and 0.82 (p=0.02 for 
improvement) respectively.  
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Conclusions 
1. Hysteroscopy is accurate in ruling in the diagnosis of endometrial cancer and hyperplasia, 
but not in ruling it out.  
2. Ultrasound is accurate in ruling out the diagnosis of endometrial cancer and hyperplasia, but 
not in ruling it in. 
3. Insufficient sample on outpatient endometrial biopsy can be anticipated when hysteroscopic 
and sonographic endometrial assessment is consistent with endometrial atrophy and in these 
cases it is not associated with pathology.   
4. The rate of hyperplasia in endometrial polyps is approximately double that in the non-
polypoidal endometrium while the cancer rate is no different.  
5. Tamoxifen treatment is associated with endometrial polyps but hormone replacement 
therapy is not. 
6. The true clinical value of a test lies in the added information over and above what was 
already known from the history and examination. It is feasible to develop a stepwise 
multivariable analytic approach to explore the added value of tests (hysteroscopy or 
ultrasonography) over and above history when predicting endometrial hyperplasia or cancer. 
This analytic strategy needs to be applied in larger datasets to draw clinical conclusions. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1  Definition 
Abnormal uterine bleeding refers to a range of abnormal premenopausal or postmenopausal uterine 
bleeding symptoms and in women of reproductive age is defined as bleeding at abnormal or 
unexpected times or by excessive flow (>80 mls) at the time of an expected menses. Any bleeding 
should be considered abnormal in post-menopausal women except for those with predictable 
withdrawal bleeding taking hormone replacement therapy (Goodman 2000). In this thesis, the term 
abnormal uterine bleeding will include the whole range of premenopausal menstrual disorders, 
postmenopausal bleeding and unscheduled bleeding on hormone replacement therapy (HRT). 
 
1.2  Prevalence 
Abnormal uterine bleeding is one of the most common gynaecologic problems that health care 
providers will face, accounting for approximately 15-20% of office visits and 25% of gynaecologic 
operations (Goodman 2000). It has an impact on many women’s quality of life. Once referred to a 
gynaecologist, surgical intervention is highly likely. Menstrual disorders occur secondary to a wide 
variety of functional and structural abnormalities. One in five women in the UK will have a 
hysterectomy before the age of 60 years. Each year around £7 million is spent on primary care 
prescriptions to treat menorrhagia, (Royal College of Obstetrics and Gynaecologists guidelines 
1998). There may be cost savings with a reduction in unnecessary tests or with the avoidance of 
inappropriate surgical intervention if the investigation process can be rationalised.  
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1.3 Prevalence of endometrial hyperplasia and cancer  
Diagnostic evaluation of abnormal uterine bleeding is carried out mainly to exclude endometrial 
carcinoma, although a malignancy is found in <10% of the cases (Lidor 1986). Only up to 10% to 
20% of cases of endometrial cancer occur before menopause, but most of these women are aged 
between 40 and 50 years (Gallop 1984; Jeffery et al., 1987). In the United Kingdom the predicted 
frequency of endometrial cancer in women aged <40 years is <12 cases per 100,000 women (Gallop 
1984; Jeffery et al., 1987; Rose 1996), whereas in women aged <20 years it is one case per 208,000 
women (Fraser 1972). 
 
Endometrial hyperplasia is considered to be a precursor for endometrial cancer and in the absence 
of therapy, progression to endometrial cancer occurs in up to 3% to 23% of cases of complex 
hyperplasia over a 13-year period (Terakawa et al., 1997). Those cases of hyperplasia with atypia 
without treatment are more likely to progress to cancer (up to 75%) than other types of hyperplasia, 
and a proportion (estimated at approximately 25%) will have undetected carcinoma of the 
endometrium at the time of the initial biopsy (Farquhar et al., 1999; Hunter 2001; Kurman et al., 
1985).  
  
1.4 Evaluating women with abnormal uterine bleeding 
Establishing diagnosis is crucial to clinical management as it allows one to choose appropriate 
treatment. Therefore evidence-based diagnosis is part of evidence-based practice; and in 
establishing accurate diagnosis, the true clinical value of a test lies in the added information over 
and above what is already known from the history and examination. 
  
Conducting investigations and establishing a diagnosis should be accomplished without delay 
particularly in women over the age of 40 years preferably in an out patient setting. This is because 
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there is a need to exclude endometrial cancer in this age group. Providing this service in out patient 
setting is both efficient and effective in that the diagnosis and the treatment (in some cases) can be 
established in one-stop consultation.  This would save patients going to theatre to have the same 
procedures performed but under general anaesthesia and would further result in time saving of staff 
and patient alike, as well as  less domestic and occupational disruption.  
 
The key to accurate, efficient diagnosis of disorders responsible for abnormal uterine bleeding 
depends on a systematic consideration of all the possible causes. Appropriate workup should be 
guided by age-related differential diagnoses for abnormal bleeding. Careful history and physical 
and pelvic examinations provide the framework for evaluation. Suspicion of reproductive tract 
malignancies is heightened in patients >40 years old, those with a history of oligoovulation or 
anovulation suggestive of long-term unopposed estrogenic exposure, those who are obese, and those 
who do not respond to first-line medical management (Long 1996). Modern diagnostic tools can 
quickly focus the evaluation and allow timely intervention. The availability of these non-invasive 
and minimally invasive diagnostic tools and minimally invasive surgical treatment has 
revolutionized the management of abnormal uterine bleeding. Advancements in technology have 
allowed considerable improvements in the resolution of many diagnostic tools. The adjunctive 
diagnostic techniques available include hysteroscopy, transvaginal ultrasonography, endometrial 
biopsy, and dilatation and curettage.  
 
1.5 Hysteroscopy  
Hysteroscopy is an important means of visualising intrauterine pathologic disorders in patients with 
various gynaecologic complaints, including menstrual disorders. Successful visualisation of the 
endometrial cavity in office hysteroscopy depends on the appropriate selection of the patient, the 
absence of contraindications, and adequate instrumentation and technique. Although clinicians were 
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limited to blind endometrial curettage or less effective imaging techniques in the past, we are now 
able to thoroughly evaluate the intrauterine environment with direct visualisation of the uterine 
cavity using the hysteroscope as an invaluable adjunct to blind endometrial sampling. Prior reports 
have revealed that in 60% of hysterectomy specimens obtained immediately after curettage the 
source of excessive bleeding was frequently not diagnosable on the curettage specimen (Stock 
1975; Word 1958). Consequently, diagnostic hysteroscopy has become increasingly popular over 
the past 20 years. In 1990 de Jong (1990) showed that office hysteroscopy under local anaesthesia is 
a reliable method for assessing the uterine cavity and it causes little discomfort (Towbin 1996). 
However, its diagnostic accuracy has not yet been established with methodologically sound 
research. 
 
1.6       Ultrasonography  
Ultrasonographic studies (particularly transvaginal), have played an increasing role in the 
evaluation of patients with menstrual disorders / abnormal uterine bleeding over the past decade, 
especially for cases of intrauterine space-occupying lesions, including endometrial polyps, and 
submucosal myomas. The accuracy of this technology has also been poorly evaluated in research. 
 
1.7 Outpatient endometrial biopsy 
Endometrial biopsy has been claimed to be a sensitive and relatively inexpensive test for identifying 
endometrial hyperplasia and carcinoma, with a reported sensitivity for the detection of endometrial 
carcinoma of approximately 85% to 95% (Lidor 1986). However, endometrial biopsy is deemed a 
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poor test for diagnosing other benign endometrial abnormalities, such as polyps and submucosal 
leiomyomas (O'Connell et al., 1998). 
 
1.8 Outpatient setting 
In the ambulatory assessment and management of women with abnormal uterine bleeding, there is 
no consensus as to which set of investigations should be implemented. While some clinicians would 
use imaging techniques as well as tissue sampling, others would advocate endoscopic examinations. 
Transvaginal ultrasound is a non-invasive method of imaging the endometrium but it may not be 
sensitive enough to detect endometrial polyps (Achiron et al., 1995; Gupta et al., 1996; Marconi et 
al., 1997). Hysteroscopy may be valuable for detecting focal lesions but less so in general 
evaluation of endometrial hyperplasia. These issues require further research. 
 
1.9 Literature review  
Unlike systematic reviews, healthcare interventions of diagnostic tests are evolving. The various 
diagnostic tests to exclude endometrial cancer and hyperplasia evaluated in this thesis are: 
hysteroscopy, ultrasonography and endometrial sampling, as outlined above. The literature was 
searched using a combination of text words and MeSH representing these tests in MEDLINE 
database (1966-2001), EMBASE (1980-2001). The search was limited to human studies. It revealed 
a dearth of existing reviews. Only two meta-analyses were identified: one on the accuracy of 
endovaginal ultrasound by (Smith-Bindman et al., 1998) and another one on the accuracy of Pipelle 
endometrial sampling by (Dijkhuizen et al., 2000). Four more systematic reviews are now published 
but were initially obtained by direct personal contact with the authors as these reviews were still in 
press at the time of writing this thesis (Clark 2002a; Clark 2002b; Clark et al., 2001; Gupta 2002). 
Table 1.1 summarises the conclusions of these six meta-analyses/systematic reviews. 
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Table 1.1: Conclusions of reviews on accuracy of tests for menstrual disorders 
 
Authors Meta-analyses/ systematic 
reviews  
Summary quantitative results Conclusions 
(Smith-
Bindman et 
al., 1998) 
 
Endovaginal ultrasound to 
exclude endometrial cancer 
and other endometrial 
abnormalities. A meta-
Analysis 
Using a 5-mm threshold to define abnormal ET, 96% (95% CI 94-98%) 
of women with cancer had an abnormal scan, whereas 92% (95% CI, 90-
93%) of women with endometrial disease (cancer, polyp, or atypical 
hyperplasia) had an abnormal result. This did not vary by HRT use. A 
woman with PMB and a 10% pre-test probability of endometrial cancer, 
has a 1% post-test probability following a normal scan  
Endovaginal ultrasound has a high sensitivity for 
detecting endometrial cancer and other endometrial 
disease and can reliably identify postmenopausal 
women with vaginal bleeding who are highly 
unlikely to have significant endometrial disease so 
that endometrial sampling may be unnecessary 
(Dijkhuizen 
et al., 2000) 
The accuracy of endometrial 
sampling in the diagnosis of 
patients with endometrial 
carcinoma and hyperplasia: a 
meta-analysis 
In both postmenopausal and premenopausal women, the Pipelle was the 
best device, with detection rates of 99. 6% and 91%, respectively. For 
the detection of atypical hyperplasia, again, the Pipelle was the most 
sensitive technique with a sensitivity of 81%.  
Endometrial biopsy with the Pipelle is superior to 
other endometrial techniques in the detection of 
endometrial carcinoma and atypical hyperplasia. The 
accuracy of the Pipelle is higher in postmenopausal 
women compared with premenopausal women.  
(Clark et al., 
2001) 
 
Accuracy of outpatient 
endometrial biopsy in the 
diagnosis of endometrial 
hyperplasia. A systematic 
quantitative review 
A positive test on outpatient biopsy diagnosed endometrial hyperplasia 
with a pooled LR of 12.0 (95% CI 7.8-18.6) while a negative test had a 
pooled LR of 0.2 (95% CI 0.1-0.3). With a positive test result, the post-
test probability of endometrial hyperplasia was 57.7% (95% CI 41.1%-
72.7%) while it was 2.2% (95% CI 0.9%-4.1%) with a negative test 
Outpatient endometrial biopsy has modest accuracy 
in diagnosing endometrial hyperplasia. 
(Clark 
2002a) 
Accuracy of outpatient 
endometrial biopsy in the 
diagnosis of endometrial 
cancer: a systematic 
quantitative review 
A positive test result on outpatient biopsy diagnosed endometrial cancer 
with a pooled LR of 66.48 (95% CI 30.04-147.13) while a negative test 
result had a pooled LR of 0.14 (95% CI 0.08-0.27). The post-test 
probability of endometrial cancer was 81.7% (95% CI 59.7%-92.9%) for 
a positive test and 0.9% (95% CI 0.4%-2.4%) for a negative test. 
Outpatient endometrial biopsy has a high overall 
accuracy in diagnosing endometrial cancer when an 
adequate specimen is obtained. A positive test result 
is more accurate for ruling in disease than a negative 
test result is for ruling it out.  
(Gupta 
2002) 
Ultrasonographic endometrial 
thickness for diagnosing 
endometrial pathology in 
women with postmenopausal 
bleeding. A meta-analysis 
Using the pooled estimates, a positive test result raised the probability of 
carcinoma from 14.0% (95% CI 13.3-14.7) to 31.3% (95% CI 26.1-
36.3), while a negative test reduced it to 2.5% (95% CI 0.9-6.4) 
Ultrasound measurement of endometrial thickness 
alone, using the evidence from the best quality 
studies cannot be used to rule in presence of 
endometrial pathology accurately in women with 
postmenopausal bleeding.  A negative result at ≤ 5 
mm cut-off level measuring both endometrial layers 
rules out endometrial pathology with good certainty 
(Clark 
2002b) 
Accuracy of hysteroscopy in 
the diagnosis of endometrial 
cancer and hyperplasia: a 
systematic quantitative review 
The pre-test probability of endometrial cancer was 3.9% (95% CI 3.7-
4.2%). A positive hysteroscopy(pooled LR 62.8, 95% CI 52.8-74.6) 
raised the probability to 71.8% (95% CI 67.0-76.6%), while a negative 
hysteroscopy (pooled LR 0.15, 95% CI 0.13-0.18) reduced the 
probability to 0.6 % (95% CI 0.5-0.8%). The 10.6% (95% CI 10.2-
11.0%) pre-test probability of endometrial disease was raised to 55.1% 
(95% CI 52.6%-57.8%) with a positive hysteroscopy (pooled LR 10.4, 
95% CI 9.7-11.1) while it was reduced to 2.8% (95% CI 2.5-3.0%) with 
a negative hysteroscopy (pooled LR 0.24, 95% CI 0.22-0.25 
The diagnostic accuracy of hysteroscopy is high for 
endometrial cancer but only moderate for 
endometrial disease (cancer and/or hyperplasia). 
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A systematic review is one in which bias has been reduced by the systematic identification, 
appraisal, synthesis, and, if relevant, statistical aggregation of all relevant studies on a specific topic 
according to a predetermined and explicit method. The Quality of Reporting of Meta-analyses 
(QUOROM) conference (Moher et al., 1999) addressed standards for improving the quality of 
reporting of meta-analyses of clinical randomised controlled trials and set items that they thought 
should be included in a checklist. Their checklist suggests that investigators explicitly describe all 
search strategies used to locate and appraise articles for inclusion in a meta-analysis. This includes 
description of the characteristics of primary studies; quantitative data synthesis; reliability and 
issues related to internal validity (Moher et al., 1999); and clinical implications related to external 
validity (or generalisability). Table 1.2 summarises the assessment of the six identified meta-
analyses/systematic reviews according to the QUOROM checklist. 
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Table 1.2: Quality assessment of reviews on accuracy of tests for menstrual disorders adopted from the QUOROM checklist  
  
Study Feature Quality assessment  
(Smith-Bindman wt 
al., 1998)   
(Dijkhuizen et 
al., 2000) 
(Clark et al., 
2001) 
(Clark  
2002a) 
(Gupta  
2002) 
(Clark 
2002b) 
Title Identify the report as a meta-analysis/ Systematic review Yes Yes Yes Yes Yes Yes 
 
Abstract Use a structured format Yes Yes Yes Yes No  Yes 
Objective The question explicitly  Yes Yes Yes Yes Yes 
Data sources The databases & other sources Yes Yes Yes Yes Yes Yes 
Review methods The selection criteria (population, intervention, outcome/ study design) 
Methods for validity assessment, data abstraction,  
   and quantitative data synthesis in sufficient  detail to permit replication 
Yes 
Yes 
Yes 
 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
 
 
Yes 
Yes 
Yes 
Yes 
Yes 
Results and 
conclusion 
 
Characteristics of studies included & excluded;  
Patient selection    
Qualitative and quantitative findings and subgroup analyses 
Yes                                Yes 
 
Yes  
Yes 
 
Yes 
Yes Yes 
 
Yes 
Yes 
 
Yes 
Introduction  Describe 
The explicit problem, the rationale for the intervention,  
   and rationale for review  
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
Methods  
Searching  
 
The information sources in details 
  
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
Selection  The inclusion and exclusion criteria Yes No Yes Yes Yes Yes 
Validity assessment   The criteria & process used Yes Yes Yes Yes  Yes Yes 
Data abstraction  The process used Yes Yes Yes Yes  Yes Yes 
Study 
characteristics  
The type of study design Yes  Yes Yes Yes  Yes Yes 
Quantitative data 
Synthesis 
  
The principal measures of effect (RR, CI) 
   handling the missing data,  heterogeneity assessment,  
   subgroup analysis and publication bias 
_ 
 
_ Yes Yes  Yes Yes 
Results  
Trial flow 
 
Meta-analysis profile  
 
No 
 
No 
 
Yes 
 
Yes  
 
Yes 
 
Yes 
Study 
characteristics  
Present descriptive data for each trial Yes  Yes Yes Yes  Yes Yes 
Quantitative data 
Synthesis  
Validity assessment present simple summary results Yes 
 
Yes Yes  Yes  Yes Yes 
Discussion
  
 
Summarise key findings, describe potential biases,  
    suggest a future  research agenda 
_ _ Yes  Yes  Yes 
 
 
Yes 
 
The existing reviews and meta-analyses only analysed data at study level. More intricate analysis 
requires the use of raw data and this is only possible with primary studies or with meta-analysis of 
individual patient data. This option needs further exploration.   
 
There remain many issues not dealt with in these reviews. For instance the prevalence of 
malignancy among endometrial polyps, and the significance of insufficient sample on endometrial 
biopsy in relation to endometrial atrophy. These issues have been raised and addressed through 
primary studies in this thesis. 
 
1.10 Endometrial polyps 
The aetiology and pathogenesis of endometrial polyps are not fully understood but polyps are 
believed to be a risk factor for endometrial cancer (Maja Jr 1996). Only a few studies have looked 
at the pathological significance of endometrial polyps (Maja 1996; Maja Jr 1996). However, the 
issue of the pathological significance of endometrial polyps has seldom been looked at in controlled 
studies. 
 
1.11 Insufficient sample 
In the ambulatory investigation of abnormal uterine bleeding, an insufficient sample is obtained 
from outpatient endometrial biopsy in 25-33% cases (Antoni et al., 1997; Gordon, Westgate et al., 
1999). Insufficient tissue has been reported in 12.8% of patients having Pipelle biopsy (Stovall et 
al., 1991). 
 
Generally, an insufficient sample is not believed to be a cause for concern because failure to obtain 
an endometrial specimen from a devise correctly positioned within the uterine cavity is considered 
to be an assurance that no significant intrauterine pathology is present (Ben Baruch et al., 1994). 
However, this issue has not so far been exposed in a multivariable analysis. 
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1.12 Questions addressed in this thesis 
With the background highlighted above this thesis raises and addresses the following research 
questions:  
This thesis addresses the following research questions:  
1. What is the accuracy of outpatient miniature hysteroscopy in the identification of 
premalignant and malignant endometrial lesions?  
2. What is the accuracy of ultrasound scan in the identification of premalignant and malignant 
endometrial lesions? 
3. What is the relative significance of hysteroscopic and ultrasonographic evidence of 
endometrial atrophy in relation to insufficient sample on outpatient endometrial biopsy? 
4. What is the risk of premalignant and malignant pathology among endometrial polyps? 
5. What is the significance of various risk factors associated with endometrial polyps? 
6. What is the feasibility of multivariable analysis to evaluate combinations of diagnostic tests 
in the diagnosis of endometrial disease? 
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CHAPTER 2 
 
THE DIAGNOSTIC ACCURACY OF OUTPATIENT MINATURE 
HYSTEROSCOPY IN PREDICTING PREMALIGNANT AND MALIGNANT 
ENDOMETRIAL LESIONS  
 
2.1 Introduction 
Menorrhagia, unscheduled bleeding on hormone replacement therapy and postmenopausal bleeding 
are common gynecological problems (Coulter 1995; Spencer 1999).  As highlighted in chapter 1, the 
main aim of investigations for abnormal uterine bleeding is to exclude endometrial carcinoma and 
its precursor, endometrial hyperplasia either complex or atypical.  This is because endometrial 
cancer is associated with abnormal uterine bleeding in over 90% of cases (Mencaglia 1995). 
Traditionally, abnormal uterine bleeding has been investigated with dilatation and curettage but 
now there is a trend towards minimally invasive investigations utilizing outpatient hysteroscopy, 
ultrasound scan and endometrial biopsy. However, the research –base underpinning these 
technologies is not as sound as one might think. The accuracy of various diagnostic tests in 
predicting premalignant and malignant endometrial lesions was not yet fully established by 
methodologically sound research at the time of conducting this original study (Al-Azzawi 1996; 
Bender et al., 1997; Cicinelli 1993; Haller 1996; Mencaglia 1995). A recent review on this topic 
provided in chapter 1 (Clark 2002b) was not yet published at the time of writing. Despite the 
evidence from this review, at the present time, the evaluation of endometrial abnormalities remains 
a subject of a continuing debate. Although reviews of literature provide summary estimates of 
accuracy for various tests from analysis of data at study level, a detailed exploration using primary 
data is essential to inform the debate about the value of tests used in abnormal uterine bleeding. 
 15
A combination of ultrasound imaging, endoscopy and tissue sampling methods remain in common 
use to help minimise diagnostic error. Hysteroscopy has been used for direct endometrial 
visualisation to establish diagnosis of intrauterine pathology. Improvements in instrumentation have 
led to the development of small diameter endoscopes with improved quality and this has meant that 
hysteroscopy can be performed on an outpatient basis (de Jong et al., 1990; Dounes 1993; Finikiotis 
1994; Gimpleson 1984; Siegler 1995). However, endoscopic interpretation has not always been 
validated against histological findings. Studies comparing hysteroscopy with traditional blind 
dilatation and curettage have suggested the superiority of the former (Gimpleson 1998; Loffer 1989; 
Saidi 1997; Saidi et al., 1997; Towbin 1996; Uno et al., 1995) but these data generally relate to 
benign disease. Therefore, the results of these studies cannot be extrapolated with confidence to the 
hysteroscopic diagnosis of premalignant and malignant endometrial lesions.  
 
There is a concern that with improvements in the quality of hysteroscopic technology a high degree 
of diagnostic accuracy is being assumed rather than established. The literature summarised in the 
review in chapter 1 revealed several relevant studies (Al-Azzawi 1996; Ben Yehuda et al., 1998; 
Gimpleson 1998; Loffer 1989; Saidi 1997; Towbin 1996; Uno LH et al., 1995) which evaluated the 
test performance characteristics of hysteroscopy, but they were generally of poor quality (Ben 
Yehuda et al., 1998; Gimpleson 1998; Loffer 1989; Saidi 1997; Towbin 1996; Uno et al., 1995). 
This background prompted this study and it addresses the first research question of this thesis: What 
is the accuracy of outpatient miniature hysteroscopy in the identification of premalignant and 
malignant endometrial lesions in women with abnormal uterine bleeding using histological 
assessment as a gold standard for the diagnosis of premalignant hyperplasia and carcinoma? 
 
 
 
 16
2.2 Ethical approval 
The studies reported in this thesis were considered by the clinical governance department and the 
Professor in charge at the time (Professor John Newton). It was felt that it was not essential to 
obtain approval from the ethics committee. Data obtained from or about the subjects was treated as 
confidential and analysed anonymously. This was in compliance with the Declaration of Helsinki 
about Ethical Principles for Medical Research involving human subjects (Press Centre of the World 
Medical Association 1996). However the ethical principles were expanded to include research 
involving human data in the year 2000 (52nd WMA General Assembly 2000). If the research was 
conducted today, it would require formal approval from Research Ethical Committee. However, in 
this thesis, the data collection and analysis were performed before the new principles in Research 
Ethics were established in the year 2000. Therefore, the ethical basis and the procedures appropriate 
at the time of conducting this work had been followed and no ethical principles were violated. 
Letters from the Chief of Research and Development Committee and from the Clinical Governance 
Manager, confirming this is attached in Appendix. 
 
2.3 Methods 
To address the above question a prospective cohort study was conducted in a rapid access ‘One-
stop’ outpatient service. Patients were referred to the service from gynaecology outpatient clinics or 
directly from general practice for investigation of abnormal uterine bleeding (menorrhagia, irregular 
menstrual loss, postmenopausal bleeding and unscheduled bleeding on tamoxifen or hormone 
replacement therapy). After consultation and counselling, a physical examination was performed, 
followed by hysteroscopy and outpatient endometrial biopsy. If the hysteroscopic view was poor or 
if the biopsy was not obtained, inpatient hysteroscopy and curettage under general anaesthesia were 
carried out. The outpatient hysteroscopy was performed after placing Instillagel (Farco-Pharma, 
Cologne, Germany) into the cervical canal via a long vaginal quill to achieve analgesia. For uterine 
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distension, normal saline solution was used with a syringe driven manually. The endoscopic 
equipment included 1.2 mm hysteroscope with 2.5 mm rigid sheath (K. Storz, Tuttlingen, 
Germany), a 175-watt xenon lamp light source and light cable, a video camera system and monitor. 
Hysteroscopy was performed by a consultant or by a senior minimal access surgery trainee. The 
depth of mucosa was evaluated by applying light pressure of the top of the endoscope against the 
endometrial surface. This evaluation was rather a subjective one based on the hysteroscopist’s 
experience. Smooth thin endometrium without vascularisation was considered normal/benign (Ben 
Yehuda et al., 1998; Cicinelli 1993). Features of increased endometrial thickness, abnormal 
vascularisation, polypoid formations, mamillations and cerebroid irregularities were considered 
suspicious lesions (Ben Yehuda et al., 1998; Cicinelli 1993; Stovall 1991). Suspicious features 
associated with irregular polylobular, friable excrescences with necrosis or bleeding were 
considered diagnostic of premalignant/malignant endometrial lesions (Cicinelli 1993). In this 
manner the hysteroscopic features were classified as negative (normal/benign), intermediate 
(suspicious lesions) or positive (diagnostic of premalignant/malignant lesions). 
 
The endometrial biopsies were performed using the Pipelle sampling device (Jaeschke 1994) 
(Laboratoire CCD, Paris, France). The Pipelle was blindly introduced in the uterine cavity to the 
fundus and the piston was withdrawn to the full length of the instrument, thereby creating negative 
pressure. As the instrument was withdrawn it was rotated drawing the tissue sample into the lumen. 
Histologic diagnoses were classified as benign (secretory/proliferative endometrium, benign 
endometrial polyp or simple hyperplasia), premalignant (complex or atypical hyperplasia) or 
malignant (carcinoma) based on the pathology report. 
 
To estimate diagnostic accuracy, independent blind comparison of hysteroscopic findings (negative, 
intermediate or positive) was carried out with the histologic diagnoses (benign, premalignant or 
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malignant). Initially, the analysis was performed by collapsing the figures into binary data to 
generate a 2x2 table with hysteroscopic features (negative or intermediate/positive) in rows and 
histologic diagnosis (benign or premalignant/malignant) in columns. These data were used to 
calculate sensitivity, specificity and predictive values along with their 95% confidence intervals 
(CI). 
 
Subsequent analysis was performed to delineate the significance of the hysteroscopic findings using 
multilevel tables. The accuracy of the various hysteroscopic features (negative, intermediate and 
positive) was statistically computed using likelihood ratio (LR) as the measure of predicting 
histologic diagnosis (Deeks 1996; Owen 1998). The imprecision around the LR values were 
estimated using 95% CI. The LR represented the ratio of the probability of a positive (or negative) 
test result in women with premalignant/malignant lesion to the probability of the same test result in 
women with benign endometrial histology. The LR indicated by how much a given hysteroscopic 
finding will raise or lower the probability of having premalignant/malignant lesion. With a positive 
hysteroscopy, an LR >1 increased the probability that premalignant/malignant lesion was present. 
The greater the LR, the larger the increase in the probability of premalignant/malignant lesion and 
the more clinically useful the test result. With a negative hysteroscopy, an LR <1 decreased the 
probability that premalignant/malignant lesion was present. The smaller the LR, the larger the 
decrease and the more clinically useful the test result.  
 
Based on the previously validated analytic methodology (Chien 2001; Department of clinical 
epidemiology and biostatistics 1981; Khan 2001), the implications of the LRs associated with 
hysteroscopic findings was examined for the different pre-test probabilities in premenopausal and 
postmenopausal women by using Bayes’ theorem to generate post-test probabilities as shown 
below: 
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  Pre-test probability = prevalence of premalignant/malignant lesion 
  Pre-test odds = pre-test probability/ (1 – pre-test probability) 
  Post-test odds = likelihood ratio x pre-test odds 
  Post-test probability = post-test odds/ (1 + post-test odds) 
An estimate of pre-test probability was obtained by calculating the prevalence of 
premalignant/malignant lesion in the different population sub-groups.  
 
2.4 Results 
During the period from November 1996 to December 1997, there were 248 patients who all had 
mini-hysteroscopy as well as histologic assessment of the endometrium. In 51/248 patients, the 
histology was obtained on inpatient assessment while in the rest the histology was obtained on 
outpatient assessment. The mean age of the patients was 50.6 years (range: 23-94) and the mean 
parity was 2.4 (range: 0-9) and there was 17 nulliparous subjects in this cohort of 248 patients. The 
reason for referral was postmenopausal bleeding in 112 (45%) patients while the rest 136 (55%) had 
premenopausal menstrual problems. Hormone replacement therapy was used by 73 (29.4%) 
women. 
 
Outpatient hysteroscopy showed negative features in 228 patients, intermediate features in 15 and 
positive features in five patients. However, on histology, premalignant/malignant lesion of the 
endometrium was found in 18 cases. There were eight cases of endometrial cancer confirmed on 
histology, one in the premenopausal group. In addition, there was one case of cancer on histology 
that was considered as negative on hysteroscopy as it was an extended primary cervical cancer. The 
reason for its exclusion was that the objective of the study was to establish the accuracy of 
hysteroscopy in predicting endometrial cancer/hyperplasia. Therefore this case was not included in 
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the analysis. Of the 10 cases of complex or atypical endometrial hyperplasia, three were in 
premenopausal and seven in postmenopausal women.  
 
The discordance between visual inspection of endometrial cavity by hysteroscopy and histologic 
diagnosis is shown in Table 2.1. Of the 228 patients classified as having normal/benign 
endometrium hysteroscopically, 12 were found to have premalignant or malignant lesion 
histologically. However, when the hysteroscopy was intermediate or positive, 14/20 turned out to 
have benign endometrial histology. Thus, the sensitivity of hysteroscopy was 33.3% (95% CI 14.4-
58.8), specificity was 93.9% (95%CI 89.8-96.5), positive predictive value was 30.3% (95%CI 12.8-
54.3), and negative predictive value was 94.7% (95%CI 90.8-97.1).  
 
Multilevel analysis using likelihood ratio revealed that for negative hysteroscopy the LR was 0.7 
(95% CI 0.5-0.9). For intermediate features at hysteroscopy the LR was 1.9 (95% CI 0.5-6.6) and 
for positive hysteroscopy it was 51.1 (95% CI 7.9-326.9) (Table 2.1). 
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Table 2.1: Diagnostic value of hysteroscopy in prediction of endometrial 
premalignant/malignant lesion. 
 
 Histologic Diagnosis+  
 Benign Premalignant Malignant Likelihood 
Ratio$ 
Hysteroscopic  
Features* 
    
 
Negative 
 
 
216 
 
8 
 
4 
 
0.7 (0.5-0.9) 
Intermediate 
 
13 1 1 1.9 (0.5-6.6) 
Positive 
 
1 1 3 51.1 (7.9-326.9) 
     
* Hysteroscopic features are classified as negative (normal/benign), intermediate (suspicious 
lesions) or positive (diagnostic of premalignant/malignant lesions).  
+ Histologic diagnoses are classified as benign (secretory/proliferative endometrium, benign polyp 
or simple hyperplasia), premalignant (complex or atypical hyperplasia) or malignant (carcinoma) 
based on the pathology report. 
$ The LR represent the ratio of the probability of a positive (intermediate or negative) test result in 
women with premalignant/malignant lesion to the probability of the same test result in women with 
benign endometrial histology. With a negative hysteroscopy, an LR <1 decreased the probability 
that premalignant/malignant lesion was present, whereas with a positive hysteroscopy, an LR >1 
increased the probability that such a lesion was present. See the methods section for a full 
description. 
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To determine if hysteroscopy was more or less useful in particular risk groups, the implication of 
these LRs on changes in probability of premalignant/malignant lesion in various risk groups was 
shown in Table 2.2.  
 
As shown in Table 2.2, in postmenopausal patients, the pre-test probability of 
premalignant/malignant lesion was 12.5%. The post-test probability of having these lesions fell to 
9.1% if the hysteroscopic findings were negative. However, with intermediate features the post-test 
probability increased to 21.3% and with positive features the probability increased substantially to 
87.9 %. In premenopausal patients, the pre-test probability of premalignant/malignant lesion was 
3.0%. The post-test probability of having these lesions reduced to 2.1% if the hysteroscopic 
findings were negative. However, with intermediate features the post-test probability increased to 
5.5%. With positive features of abnormality the probability increased to 61.2%. This meant that 
miniature hysteroscopy had limited value in low risk patients but it was likely to be of some use in a 
high-risk group of patients. 
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Table 2.2: Diagnostic value of hysteroscopy in prediction of endometrial 
premalignant/malignant lesion in postmenopausal and premenopausal women. 
 
Pre-test probability of 
premalignant/malignant 
lesion* 
Hysteroscopic 
Features+ 
Post-test probability of 
premalignant/malignant 
lesion 
   
Postmenopausal women   
12.5% 
(14/112) 
Negative 
 
9.1% 
 Intermediate 
 
21.3% 
 Positive 87.9% 
   
Premenopausal women   
3.0% 
(4/136) 
Negative 
 
2.1% 
 Intermediate 
 
5.5% 
 Positive 
 
61.2% 
* An estimate of pre-test probability is obtained by calculating the prevalence of 
premalignant/malignant lesion in the different population sub-groups. 
+ Hysteroscopic features are classified as negative (normal/benign), intermediate (suspicious 
lesions) or positive (diagnostic of premalignant/malignant lesions). See methods section for full 
description. 
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2.5 Discussion 
The proposed structure by Docherty and Smith (Docherty 1999) for the discussion of scientific 
papers is used in this chapter and all other chapters for discussion in the following order:   
• Statement of principal findings  
• Appraisal of quality of the study: Strengths and weaknesses of the study  
• Relation to other studies considering differences in quality and results 
• Meaning of the study: possible mechanisms and implications for clinicians or policymakers  
• Unanswered questions and future research  
 
2.5.1 Principal findings of the study 
This study showed that negative or intermediate findings at hysteroscopy are not conclusive in the 
prediction of endometrial premalignant/malignant lesion. This meant that the probability of 
premalignant/malignant lesion was not particularly altered by the knowledge of normal 
hysteroscopic appearances. However, if the findings were definitely positive of abnormality, the LR 
was large and it substantially increased the post-test probability of confirming 
premalignant/malignant lesion. Furthermore this study showed that miniature hysteroscopy had 
limited value in low risk patients but it was likely to be of some use in a high-risk group of patients. 
As normal findings do not eliminate the need for endometrial sampling, miniature hysteroscopy is 
not a substitute for histopathological assessment in an outpatient diagnostic service.  
 
2.5.2 Appraisal of quality of the study 
The strength of this study and the credibility of its findings depend on the strength of the 
methodology. This is made clear by adhering to the checklist proposed by the STARD group 
(Standards for Reporting of Diagnostic Accuracy), the objective of which is to improve the  
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quality of reporting of studies on diagnostic accuracy in order to detect the potential for bias in the 
study (Table 2.3).  
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Table 2.3: Application of STARD checklist to the study reported in Chapter 2 
Section and topic Description of the criteria 
Compliance 
of thesis 
METHODS 
Participants:  
                    Study population 
                    Setting/ Location  
                    Recruitment:  
 
Based on presenting symptoms, the participants had received the index test(s) and the reference standard? 
 
Yes 
                     Participant sampling: Consecutive series of patients defined by selection criteria Yes 
                     Data collection: Participants identified and data collected before the index test(s) and reference standards were performed 
(prospective study) 
Yes 
Reference standard  and its rationale Yes 
Test methods 
 
Technical specification of given material and methods Yes 
 Definition and rationale for the units, cut-offs and/or categories of the results of the index test(s) and the 
reference standard 
Yes 
 The number, training and expertise of the persons (a) executing and (b) reading the index test(s)  
and the reference standard 
Yes 
 Methods for calculating measures of diagnostic accuracy or making comparisons, the statistical methods 
used to quantify uncertainty (e.g. 95% CI) and methods for calculating test reproducibility 
Yes 
RESULTS 
Participants 
 
When study was done, including beginning and ending dates of recruitment 
 
Yes 
 Clinical and demographic characteristics (e.g. age, sex, spectrum of presenting symptom(s), co morbidity, 
current treatment(s), recruitment centre) 
Yes 
Test results A cross tabulation of the results of the index test(s) by the results of the reference standard;  
for continuous results, the distribution of the test results by the results of the reference standard 
 
Indeterminate results, missing responses and  outliers of index test(s) stratified by reference standard result 
and how they were handled  
Yes 
 
 
Yes 
 
Estimation Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% CI)  
 
Estimates of variability of diagnostic accuracy between subgroups of participants (Post vs premenopausal) 
 
Yes 
 
Yes 
 
 
The criteria that distinguish a definitely useful clinical test from one that is of doubtful value are 
generally well established and have been embodied in the rules of critical appraisal of the medical 
literature (Chien 1997; Deeks 1996; Department of clinical epidemiology and biostatistics 1981; 
Greenhalgh 1997; Jaeschke et al., 1994; Owen 1998). According to these rules, the new and more 
powerful concepts around LRs are preferable to the old-fashioned ideas of sensitivity and 
specificity in the assessment of the clinical value of a test. By applying the criteria for usefulness of 
a test based on LRs, a diagnostic test study can more meaningfully summarise the findings of the 
research, minimising the risk of erroneous inferences. For a negative test result LR <0.1 is regarded 
as definitely useful, 0.1-0.2 is regarded as moderately useful, 0.5-0.2 is regarded as slightly useful, 
and 0.5-1 is regarded as not at all useful. For a positive test result, LR >10 is regarded as definitely 
useful, LR 5-10 is regarded as moderately useful, LR 2-5 is regarded as slightly useful, and LR 1-2 
is regarded as not at all useful. When applied to the study’s results, these criteria indicate that a 
negative or intermediate hysteroscopy was not at all useful but a positive hysteroscopy was 
definitely useful. 
 
2.5.3 Relation to other studies considering differences in quality and results 
Is it surprising that an examination involving direct visualisation of the entire uterine cavity with 
excellent image quality and magnification has limited diagnostic value as shown in this study? To 
answer this question, the results based on more traditional concepts evaluating diagnostic accuracy 
of hysteroscopy were compared with this study. This study’s analysis showed that hysteroscopy had 
a sensitivity of 33.3% (95% CI 14.4-58.8) and specificity of 93.9% (95% CI 89.8-96.5) in the 
detection of premalignant/malignant lesions. Similarly, Haller et al quoted sensitivity of 50% and 
specificity of 100% for endometrial carcinoma and Uno et al (Uno LH et al., 1995) reported 
sensitivity of 15.8% and specificity of 97.3% for endometrial hyperplasia. As a sensitive test when 
negative rules out disease, it is clear that the appropriate inference should be that a normal 
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hysteroscopy is poor in ruling out cancer or hyperplasia. Ben Yehuda et al (1998) also reached a 
conclusion of poor diagnostic performance for hysteroscopy in the prediction of hyperplasia and 
cancer, which concurs with my inferences.  
 
With the lack of rigorous evidence in this field, this primary study was the original work that 
prompted the systematic review within our group (Clark 2002b). The results of this systematic 
review confirmed the findings of this primary study. It revealed that for endometrial cancer a 
positive hysteroscopy had a pooled LR of 62.8 (95% CI 52.8-74.6), while a negative hysteroscopy 
had a pooled LR of 0.15 (95% CI 0.13-0.18). The review concluded that the diagnostic accuracy of 
hysteroscopy is high for endometrial cancer but only moderate for endometrial disease defined as 
cancer and/or hyperplasia, an approach that has been used in an earlier review of endometrial 
ultrasound (Smith-Bindman et al., 1998). 
 
2.5.4 Practical implications for clinicians  
Hysteroscopy is highly accurate and thereby clinically useful in diagnosing endometrial cancer in 
women with abnormal uterine bleeding. Endometrial sampling and/or ultrasonography should be 
considered with negative hysteroscopy, as negative hysteroscopy is not conclusive for excluding 
malignancy.  
 
2.5.5 Implications on research  
• Guideline or national consensus on how to investigate menstrual disorders/abnormal uterine 
bleeding is needed. Such a guideline was recently published in Scotland (the Scottish 
Intercollegiate Guideline Network 2002).  
• Systematic reviews using Individual Patients Data or large primary studies are needed to 
evaluate accuracy of combinations of tests used in ambulatory assessment of menstrual  
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disorders. 
• An estimate of the effectiveness and cost effectiveness estimation of the available diagnostic 
tools (hysteroscopy /ultrasound /biopsy) are required. 
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CHAPTER 3 
 
THE DIAGNOSTIC ACCURACY OF ULTRASOUND SCAN IN 
PREDICTING ENDOMETRIAL HYPERPLASIA AND CANCER IN 
POSTMENOPAUSAL BLEEDING 
 
3.1.1 Introduction 
The rate of endometrial cancer and hyperplasia in cases of postmenopausal bleeding is over 10-15% 
and the investigations for this condition are aimed at identifying these pathological conditions 
(Gupta et al., 1996; Mencaglia 1995) . As highlighted in chapter 1, postmenopausal bleeding has 
ttraditionally been investigated with dilatation and curettage but now there is a trend towards 
minimally invasive investigations utilizing ultrasound scan, outpatient hysteroscopy, and 
endometrial biopsy. However, at the time of conducting this primary study, the accuracy of various 
diagnostic tests in predicting premalignant and malignant endometrial lesions was not yet fully 
established by methodologically sound research. The reviews in this field summarised in Chapter 1 
(Smith-Bindman et al., 1998; Gupta 2002) were not yet published. However, even given the 
evidence from these reviews, the evaluation of endometrial abnormalities remains a subject of 
continuing debate. Although reviews of literature provide summary estimates of accuracy for 
various tests from analysis of data at study level, a detailed exploration using primary data is 
essential to inform the debate about the value of tests used in postmenopausal bleeding. 
 
A combination of ultrasound imaging, endoscopy and tissue sampling methods are employed to 
minimise diagnostic error in the assessment of postmenopausal bleeding. While some researchers 
consider hysteroscopy to be the standard of care (Dubimsky 1997), others have suggested that non-
 31
invasive assessment using ultrasound may exclude endometrial pathology in postmenopausal 
women. Advances in technology have made possible the introduction of transvaginal ultrasound 
scanning using higher frequency ultrasound with greater proximity to the uterus. Hence, the 
endometrial-myometrial interface can be more clearly delineated than with the full bladder 
transabdominal technique. 
 
The ultrasound endometrial echogenicity associated with the presence of glands and mucin is 
proportional to the growth and differentiation of the endometrium (Dorum 1993). Therefore, the 
endometrium of a normal atrophic uterus is thin, on average measuring 2.3mm by sonography 
(Fleisher 1996; Nasri 1989; Nasri 1991). Endometrial thickness (ET) test might be considered 
negative when the measurement is <5mm in women who are not receiving estrogen replacement 
therapy (Nasri 1989) and in these cases histological examination might not be needed (Granberg 
1991). However, advanced carcinoma with minimal lesions is known to occur in cases without 
noticeable ultrasonic thickness of the endometrium (Dorum 1993; Gupta et al., 1996). With this 
background, this study was carried out to address the following research question: What is the 
accuracy of ultrasound scan in the identification of premalignant and malignant endometrial lesions 
in women with postmenopausal bleeding using histological assessment as a gold standard for the 
diagnosis of endometrial cancer and hyperplasia?  
 
3.1.2 The effects of hormone replacement therapy on the endometrium 
There is evidence that unopposed oestrogen therapy may induce endometrial stimulation and 
increase the risk of endometrial hyperplasia, atypia, and the potential for endometrial carcinoma. 
Pickar et al’s review provides confirmation that the addition of progestogens administered either 
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cyclically or continuously, provides protection against endometrial hyperplasia (Pickar et al., 1998). 
The continuous presence of progestogens causes down-regulation of oestrogen and progestogens 
receptors and endometrial atrophy. The addition of progestogens may cause unwanted side effects 
such as unscheduled bleeding. However unscheduled bleeding is less likely under sequential than 
continuous therapy (Lethaby 2003).  
 
One randomized, comparative study (Hanggi 1997) in postmenopausal women was designed to 
evaluate the endometrium under the effect of sequential HRT. It compared transvaginal 
ultrasonography immediately before Pipelle biopsy at baseline and subsequently after 12 and 24 
months in those patients taking HRT and those who were not.  The study found that after 24 
months, endometrial thickness was increased in the HRT group comparing to the controls (P < 
0.001). Moreover the study found that if endometrial thickness was <5 mm, the endometrial biopsy 
sample was either inactive/atrophic or insufficient for histopathological diagnosis. Hyperplastic or 
malignant changes were not reported.  
 
The Nordic multicenter study (Granberg 1997) revealed that atrophy was found significantly more 
often in women without HRT. Hormonal effects on the endometrium were found significantly more 
often in women with HRT (sequential). Endometrial hyperplasia was found most commonly in 
women with oestrogen as compared to those with HRT (sequential) and without HRT. Endometrial 
cancer occurs most in women without HRT. Endometrial cancer did not occur in any woman (with 
oestrogen, sequential HRT, or without HRT) with an endometrial thickness of <4 mm.  
 
It is in general true that the thicker the endometrium of a postmenopausal woman the higher the 
likelihood of endometrial cancer being present (Wolman 1998). The threshold value for deciding if 
there is a significant risk of cancer will depend, in part, on the “normal” endometrial thickness for 
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the relevant patient group. For example, women on sequential HRT tend to have thicker 
endometria, compared to those who have never used HRT, have not used any form of HRT for a 
year or more, or are using continuous combined HRT, and so a higher threshold needs to be used 
for identifying those with a significant probability of cancer (Scottish Intercollegiate Guidelines 
Network 2002).  
 
3.2 Methods 
A prospective cohort study was conducted in a rapid access ‘One-stop’ outpatient service in two 
large centres: Birmingham Minimal Access and Surgical Training centre (MAST), and 
Gynaecology Minimal Access Unit (GMAU), Ninewells Hospital, Dundee (see Appendix 2). The 
ethical considerations are covered in Section 2.2.  
 
This study recruited 96 consecutive postmenopausal women, 44 referred to the MAST centre and 
52 to the GMAU between November 1996 and December 1997. These patients were referred from 
gynaecology outpatient clinics or directly from general practice for the investigation of 
postmenopausal bleeding defined as vaginal bleeding at least six months after cessation of the 
menses. Contrary to chapter 2, this chapter’s population included only women with postmenopausal 
bleeding because endometrial thickness on ultrasound scan is significant only in this group of 
women (postmenopausal), unlike hysteroscopy where it may be performed as an investigation for 
the entire spectrum of menstrual disorders in any age group.  
 
After consultation and counselling, a physical examination was performed followed by transvaginal 
ultrasound scan of the pelvis and uterus using a portable scanner with an endovaginal 6.5 MHz 
transducer (Hitachi Sumi, Japan). Trained ultrasonographers carried out the scans. In order to 
reduce the inter-operator variability and be able to further generalise the results, the following 
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criteria were followed in both centres: the transducer was introduced into the posterior vaginal 
fornix, and the uterus was scanned longitudinally and transversely. The measurements of the 
endometrium were performed in the longitudinal planes, and scanning from cornua to cornua 
identified the thickest part. The measurement was performed between the two basal layers of the 
anterior and posterior uterine wall without including the measurements of any polyp and/or fluid 
that might be in the cavity (Dorum 1993; Gupta et al., 1996; Karlsson 1995).  
 
As a gold standard, the histopathologic diagnosis was used based on outpatient endometrial biopsies 
or inpatient curettage. Pipelle sampler was the device used to perform the endometrial biopsies 
(Laboratoire CCD, Paris, France) (Stovall 1991). The Pipelle was introduced in the uterine cavity to 
the fundus, and to create negative pressure the piston was withdrawn to the full length of the 
instrument. As the instrument was withdrawn it was rotated drawing the tissue sample into the 
lumen. Histologic diagnoses were classified as benign (secretory/proliferative endometrium, benign 
endometrial polyp), hyperplasia (simple, complex and atypical) equal to premalignant in Chapter 2, 
or malignant (carcinoma) based on the pathology report.  
 
To estimate the diagnostic accuracy of endometrial thickness on ultrasound examination, the 
findings were blindly compared with the histologic diagnosis. Based on the work by Karlsson et al., 
(1995), endometrium thickness >4.0mm was used as the cut-off level for abnormality. Initially, the 
analysis was performed by collapsing the figures into binary data to generate a 2x2 table with 
endometrial thicknesses (<4.0mm or >4.0mm) in columns and histologic diagnosis (benign or 
hyperplasia/cancer) in rows. These data were used to calculate sensitivity, specificity and predictive 
values along with their 95% CI. Subsequent analysis was performed to delineate the significance of 
the ultrasonographic endometrial thickness using multilevel tables. The accuracy of the various 
endometrial thicknesses (<4.0mm, 4.1-9.0mm, >9.0mm) was statistically computed using LR as the 
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measurement of predicting histologic abnormality (Deeks 1996; Jaeschke 1994). Setting these three 
cut-off values was arbitrary. The imprecision around the LR values was estimated using 95% CI. 
The descriptions of LR’s are covered in Section 2.3.  
 
Based on the previously validated analytical methodology (Khan 2001; Chien 2001; Owen 1998), 
the implications of the LRs associated with ultrasonographic endometrial thickness for the different 
pre-test probabilities in postmenopausal women were examined by using Bayes’ theorem to 
generate post-test probabilities as shown in Section 2.3. An estimate of pre-test probability was 
obtained by calculating the prevalence of premalignant/malignant lesion in the study population. 
 
3.3 Results 
The mean age of the patients was 52.3 years (range: 42-94) and the mean parity was 2.4 (range: 0-
9). Ultrasound scans showed endometrial thickness <4.0mm in 42 patients, endometrial thickness 
4.1-9.0mm in 29 and endometrial thickness >9.0mm in 25 patients. However, on histology, 
endometrial hyperplasia/cancer was found in 14 cases. There were 11 cases of endometrial cancers, 
five in the MAST centre and six in the GMAU; and there were three cases of endometrial 
hyperplasia, one in the MAST centre and two in the GMAU. Not a single case of malignancy was 
found when the endometrial thickness was <4.0mm. The one case of hyperplasia that was found in 
this group was simple hyperplasia. The 11 cases of carcinoma had endometrial thickness >4.0mm. 
 
Of the total of 96, 46 patients (47.9%) were on hormone replacement therapy (HRT) either 
continuous combined or sequential combined [32/44 (72.7%) in the MAST centre and 14/52 
(26.9%) in the GMAU]. There was one case of cancer and two of hyperplasia among HRT users. In 
the MAST centre, one patient had hyperplasia and the endometrial thickness was 4mm in this case. 
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In the GMAU, one woman had cancer and the endometrial thickness was 7mm in this case, while 
another one had hyperplasia and the endometrial thickness in this case was 5mm. 
The discordance between ultrasonographic endometrial thickness and histologic diagnosis is shown 
in Table 3.1. For detection of endometrial hyperplasia/carcinoma, endometrial thickness >4.0mm 
had a sensitivity of 92.9% (95%CI 64.2-99.6), specificity of 50% (95%CI 38.8-61.2), a positive 
predictive value of 24.1% (95%CI 13.9-37.9), and a negative predictive value of 97.6% (95%CI 
85.9-99.9). 
 
Multilevel analysis using likelihood ratio revealed that for endometrial thickness  
<4.0mm at ultrasound scan the LR was 0.14 (95%CI 0.02-0.64). For ET: 4.1-9.0mm at ultrasound 
scan the LR was 0.94 (95%CI 0.37-1.99) and for endometrial thickness >9.0mm it was 3.3 (95%CI 
1.73-5.73) (Table 3.1).  
 
The implication of these LRs on changes in probability of premalignant/malignant lesion is shown 
in Table 3.2. The table shows that in postmenopausal patients, the pre-test probability of 
endometrial hyperplasia/cancer was 15.0%. The post-test probability of having these lesions fell to 
2.4% if endometrial thickness <4.0mm. However, with endometrial thickness 4.1-9.0mm the post-
test probability changed to 14.2% and with endometrial thickness >9.0mm the probability increased 
to 36.8%.  
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Table 3.1: Diagnostic value of ultrasound scan in diagnosis of endometrial cancer and 
hyperplasia 
 
 Histology Benign Hyperplasia Carcinoma Likelihood 
Ratio 
Endometrial 
Thickness 
     
<4.0mm  41 1 
 
0 
 
0.14 
(0.02-0.64) 
4.1-9.0mm  25 1 3 0.94 
(0.37-1.99) 
>9.0mm  16 1 8 3.3 
(1.73-5.73) 
      
+ Histologic diagnoses are classified as benign (secretory/proliferative endometrium, benign polyp), 
hyperplasia (simple, complex, or atypical) or malignant (carcinoma) based on the pathology report. 
$ The LR represents the ratio of the probability of a positive test result in women with endometrial 
cancer/hyperplasia to the probability of the same test result in women with benign endometrial 
histology. An LR <1 decreases the probability that endometrial cancer/hyperplasia is present, 
whereas an LR >1 increases the probability that such a lesion is present. See the methods section for 
a full description. 
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Table 3.2: Diagnostic value of ultrasound scan in diagnosis of endometrial cancer or 
hyperplasia 
 
Pre-test probability of * Endometrial   Post-test probability of  
endometrial                            thickness   endometrial 
hyperplasia/cancer                                                 hyperplasia/cancer 
 
   
15% (14/96) <4.0 mm  2.4 % 
  
 4.1-9.0 mm 14.2 % 
  
 >9.0 mm 36.8 % 
    
 
* An estimate of pre-test probability is obtained by calculating the prevalence of endometrial 
hyperplasia/cancer in the study population.  
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3.4 Discussion  
3.4.1 Principal findings of the study: 
This study concluded that endometrial thickness at ultrasound scan is not conclusive in the 
prediction of endometrial hyperplasia/cancer but it is reliable in excluding such a lesion if 
endometrial thickness is ≤4.0mm although this finding does not totally eliminate the need for 
endometrial sampling as there was one case of simple hyperplasia found in this group. This meant 
that in women with postmenopausal bleeding, malignancy might be safely excluded if sonographic 
endometrial thickness was <4.0mm. However, the probability of endometrial hyperplasia/cancer is 
not particularly altered by the knowledge that endometrial thickness on scan was 4.1-9.0mm. For an 
endometrial thickness >9.0mm, the likelihood of endometrial hyperplasia/cancer is only slightly 
increased.    
 
3.4.2 Appraisal of quality of the study 
The strength of this study and the credibility of its findings depend on the strength of the 
methodology. This is made clear by adhering to the checklist proposed by the STARD group 
(Standards for Reporting of Diagnostic Accuracy), the objective of which is to improve the quality 
of reporting of studies on diagnostic accuracy allowing to detect the potential for bias in the study. 
(Table 3.3).
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Table 3.3: Application of STARD checklist to the study reported in Chapter 3  
Section and topic Description of the criteria 
Compliance 
of this study 
METHODS 
Participants:  
                    Study population 
                    Setting/ Location  
                    Recruitment:  
 
Based on presenting symptoms, the participants had received the index test(s) and the reference standard? 
 
Yes 
                     Participant sampling: Consecutive series of patients defined by selection criteria Yes 
                     Data collection: Participants identified and data collected before the index test(s) and reference standards were performed 
(prospective study) 
Yes 
Reference standard  and its rationale Yes 
Test methods 
 
Technical specification of Given material and methods Yes 
 Definition and rationale for the units, cut-offs and/or categories of the results of the index test(s) and the 
reference standard 
Yes 
 The number, training and expertise of the persons (a) executing and (b) reading the index test(s)  
and the reference standard 
Yes 
 Methods for calculating measures of diagnostic accuracy or making comparisons,  the statistical methods 
used to quantify uncertainty (e.g. 95% CI) and methods for calculating test reproducibility 
Yes 
RESULTS 
Participants 
 
When study was done, including beginning and ending dates of recruitment 
 
Yes 
 Clinical and demographic characteristics (e.g. age, sex, spectrum of presenting symptom(s), co morbidity, 
current treatment(s), recruitment centre) 
Yes 
Test results A cross tabulation of the results of the index test(s) by the results of the reference standard;  
for continuous results, the distribution of the test results by the results of the reference standard 
 
Indeterminate results, missing responses and  outliers of index test(s) stratified by reference standard result 
and how they were handled  
Yes 
 
 
Yes 
 
Estimation Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% CI)  
 
Estimates of variability of diagnostic accuracy between subgroups of participants (Post vs premenopausal) 
 
Yes  
 
Yes 
 
 
In the rules of critical appraisal of the medical literature, the criteria that distinguish a definitely 
useful clinical test from one that is of doubtful value are discussed in Section 2.5.2.  
 
This study may be criticised as being flawed as the analytic strategy did not perform separate 
statistics for the subgroup of women using HRT. The data on HRT use in postmenopausal bleeding 
was explored and revealed that despite half of the patients being on HRT (46/96), only one of the 11 
patients of cancers occurred in HRT users. The endometrial thickness in this case was abnormal at 
7mm. Keeping in mind that in this study, endometrial cancer did not occur in any women (with or 
without HRT) with an endometrial thickness of <4mm, it is safe to conclude that the findings about 
the prediction of malignant disease were not particularly influenced by HRT use. However, the 
results on premalignant disease were somewhat inconsistent with those of Granberg et al., (1997) 
who reported that endometrial hyperplasia was found most commonly in women on oestriol in the 
endometrial thickness group 5-8mm (see 3.2.2). In two patients on HRT with endometrial 
hyperplasia in the thesis’ study, the endometrial thickness was 4mm and 5mm. 
 
3.4.3 Relation to other studies considering differences in quality and results 
Is it surprising that an examination involving excellent image quality such as ultrasound scan has 
limited diagnostic value in our study? To answer this question, these results were compared with 
other studies that were generally based on more traditional concepts of evaluating diagnostic 
accuracy. Based on their analyses, Granberg et al., (1991) and Nasri et al., (1989) have suggested 
that an endometrial thickness of 5mm is an appropriate cut off level for conservative management 
of patients with postmenopausal bleeding while Giusa- Chiferi et al., (1996) recommended no need 
for anatomopathologic tests when the thickness is <3mm. However, (Dorum et al., 1993) quoting 
sensitivity of 80% and specificity of 60%, concluded that scan was not accurate enough to replace 
histologic examination of the endometrium for detecting endometrial malignancy. In their 
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interesting study Kufahl (1997) found that at a cut-off limit of 4mm, the sensitivity of the 
ultrasound was 90.3%, the specificity 24.8%, the positive predictive value 21.4% and the negative 
predictive value 91.9%. One endometrial cancer, one atypical and one complex hyperplasia were 
missed.  
 
In their large multicentre study Karlsson et al., (1995) concluded that the risk of finding pathologic 
endometrium at curettage is 5.5% when the endometrium is ≤4.0mm as measured by transvaginal 
ultrasonography.  Thus in women with postmenopausal bleeding and an endometrium ≤4.0mm, it 
would seem justified to refrain from curettage. Dubimsky et al., (1997) reported that transvaginal 
ultrasound appears to be more sensitive than endometrial biopsy for the detection of endometrial 
abnormalities. Saidi et al., (1997) have quoted a sensitivity of 95% and a specificity of 65% for 
transvaginal ultrasonography in detecting abnormal findings. 
 
Recently, there has been a metaanalysis carried out by Smith-Bindman et al., (1998) to determine 
the accuracy of transvaginal scan in detecting endometrial disease in postmenopausal women with 
vaginal bleeding according to hormone replacement use. The overall summary mean weighted 
estimates of sensitivity and specificity were calculated for thresholds of endometrial thickness from 
3 to 10 mm. Using a 5-mm threshold to define abnormal endometrial thickening, 96% (95% CI 94-
98%) of women with cancer had an abnormal scan result, whereas 92% (95% CI 90-93%) of 
women with endometrial disease (cancer, polyp, or atypical hyperplasia) had an abnormal result. 
This did not vary by hormone replacement use. However, the number of women with normal 
histology who had an abnormal scan result did vary by hormone replacement use. In women who 
were not using hormone replacement therapy, 593 (8%) with normal histological findings had an 
abnormal ultrasound result (specificity, 92%; 95% CI 90-94%), whereas 1544 (23%) using hormone 
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replacement therapy had an abnormal scan result (specificity, 77%; 95% CI 75-79%). For a 
postmenopausal woman with vaginal bleeding with a 10% pre-test probability of endometrial 
cancer, her probability of cancer is 1% following a normal scan result. The conclusion from this 
meta analysis confirmed my findings that transvaginal ultrasound has a high sensitivity for ruling 
out endometrial cancer and other endometrial disease and can reliably identify postmenopausal 
women with vaginal bleeding who are highly unlikely to have significant endometrial disease. 
Therefore endometrial sampling may be unnecessary. 
 
The primary study reported in this Chapter has been the original work that prompted the systematic 
review within our group jointly with the Ninewells centre. The results of this systematic review 
confirmed the findings of my primary study. Using the pooled estimates, a positive test result raised 
the probability of carcinoma to 31.3% (95% CI 26.1 - 36.3), while a negative test reduced it to 2.5% 
(95% CI 0.9 - 6.4).  The review concluded that ultrasound measurement of endometrial thickness 
alone, using the evidence from the best quality studies couldn’t be used to rule in presence of 
endometrial pathology accurately in women with postmenopausal bleeding.  However, a negative 
result at ≤ 5mm cut-off level measuring both endometrial layers rules out endometrial pathology 
with good certainty (Gupta 2002). 
 
Some reviewers prefer to give the rationale (by giving Receiver Operating Characteristic curve 
analysis) on how the various cut-off levels for normal measurement of endometrial thickness was 
arrived at for each of the above mentioned studies, however, most of these study are not powered 
enough to use the ROC. Moreover, in my opinion, the ROC lack the clinical usefulness as clinicians 
find it difficult to interpret. 
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3.4.4 Practical implications for clinicians  
Endometrial sampling may safely be omitted in women with postmenopausal bleeding, if 
sonographic endometrial thickness is <4.0mm provided the whole cavity is adequately examined  
and it is regular. 
 
Improvements in the technology might improve the accuracy of sonography in detecting 
endometrial hyperplasia/cancer in the future. It has been suggested that transvaginal colour and 
pulsed doppler sonography may help in improving differentiation of malignant from benign 
endometrial pathologic conditions in postmenopausal women (Aleem et al., 1995).  
 
3.4.5 Implications on research 
• National guideline or national consensus on how to investigate menstrual 
disorders/abnormal uterine bleeding is needed. Such a guideline was although published in 
Scotland (the Scottish Intercollegiate Guideline Network 2002). 
• Systematic reviews using Individual Patients Data of relevant or large primary studies are 
needed to evaluate the accuracy of combinations of tests used in ambulatory assessment of 
menstrual disorders (see Chapter 7). 
• The effectiveness and cost effectiveness estimation of the available diagnostic tools 
(hysteroscopy /ultrasound /biopsy) are required. 
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CHAPTER 4 
 
CONTROLLED ANALYSIS OF FACTORS ASSOCIATED WITH 
INSUFFICIENT SAMPLE ON OUTPATIENT ENDOMETRIAL BIOPSY 
 
4.1 Introduction 
In ambulatory investigation of abnormal uterine bleeding, an insufficient sample is obtained from 
outpatient endometrial biopsy in 25-33% cases (Antoni et al., 1997; Gordon et al., 1999). 
Generally, an insufficient sample is not believed to be a cause for concern as failure to obtain an 
endometrial specimen from a devise correctly positioned within the uterine cavity is considered to 
be an assurance that no significant intrauterine pathology is present (Ben Baruch et al., 1994). Do 
we have the confidence that insufficient sample is benign in women with abnormal uterine 
bleeding? One study supporting this view (Choo 1985) showed that in 42% of cases with 
hysteroscopically atrophic endometrium, no tissue was obtained on traditional dilatation and 
curettage for histological assessment. Such data provide a plausible, but not scientific, evidence of 
association because of a lack of a comparison with a hysteroscopically normal control group. 
Moreover, such data also suffers from lack of an adjustment for confounding variables like age, 
menopausal status and ultrasonographic endometrial thickness. Quite apart from this 
methodological debate, information obtained from inpatient dilatation and curettage can hardly be 
considered generalisable to outpatient biopsy devices. 
 
To have the confidence that insufficient sample on outpatient biopsy is benign in women with 
abnormal uterine bleeding; the following question should be answered:  
What is the relative significance of hysteroscopic and ultrasonographic evidence of endometrial 
atrophy in relation to insufficient sample on outpatient endometrial biopsy? 
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4.2 Methods  
To answer the above question, a controlled statistical analysis was conducted to delineate the 
relative significance of factors associated with insufficient sample on outpatient endometrial biopsy.  
 
The database of 248 consecutive patients with abnormal uterine bleeding investigated in the One-
stop clinic from November 1996 to December 1997 was used (Bakour 1999). Ethical considerations 
were discussed in Section 2.2.  
 
 In the clinic, a combination of pelvic ultrasound scan, outpatient hysteroscopy, and Pipelle 
endometrial sampling were performed. Pelvic transvaginal ultrasonography was performed using a 
portable scanner (Hitachi Sumi, Japan) with an endovaginal 6.5 MHz transducer. Endometrial 
thickness was measured in mm including both layers of the endometrium. Outpatient hysteroscopy 
was performed using 1.2mm micro-hysteroscope with 2.5mm outer rigid sheath (Karl Storz, 
Tuttlingen, Germany). Assessing the depth of mucosa by applying light pressure of the top of the 
endoscope, hysteroscopic appearances of thin smooth non-vascular endometrium were considered 
to be atrophic. Outpatient endometrial biopsies were performed using Pipelle sampling device 
(Laboratoire CCD, Paris, France). Of the 248 patients, 74 (29.8%) had insufficient endometrial 
sample on pathology report. All 74 women were followed using the hospital clinical computer 
system for any further admission episodes related to abnormal uterine bleeding over a period of two 
years. Inpatient assessment with sampling was performed on those with recurrent symptoms. None 
of these patients had endometrial cancer or hyperplasia. 
 
To delineate the relative significance of various factors (independent variables) on sufficiency of 
outpatient endometrial biopsy (binary dependent variable), a multivariable logistic regression model 
(Khan 1999) was built. The primary null hypothesis we wanted to test was, “the value of the β-
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coefficient for the various risk factors in the logistic model is zero or its exp (β) is 1.0. To obtain a 
valid estimate of the association between endometrial atrophy (on hysteroscopy and on 
ultrasonography) and insufficient endometrial specimen, the analysis was adjusted for the 
confounding effects of age, menopausal status, parity and use of hormone therapy by including 
them as independent variables in the multivariable logistic regression analysis. In the model 
building process, the significance of the independent variables was tested individually and in 
various combinations. Variables were tested for interaction and they were analysed using both 
nominal and continuous scales of measurement. The assumption of linearity of association was 
checked for the different independent variables. Cases with missing data were excluded from the 
multivariable analysis. The model that best predicted the odds of insufficient sample on endometrial 
biopsy with the lowest deviance and highest goodness of fit was selected. The Hosmer-Lemeshow 
test using the "deciles of risk" method was used to assess the goodness of fit. 
 
4.3 Results 
The characteristics of the women attending the One-stop clinic were shown in Table 4.1.  
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Table 4.1: Characteristics of women attending outpatient One-stop hysteroscopy clinic 
Patients’ 
Characteristics 
 
 
Sufficient sample 
on endometrial biopsy 
N=174 
 
Insufficient sample 
on endometrial biopsy 
N=74 
Age - years 
Mean (95% CI) 
 
 
Parity 
Mean (95% CI) 
 
 
Post menopause 
n % (95% CI) 
 
 
Hormone 
Replacement 
Therapy 
n % (95% CI) 
 
 
Cancer 
n % (95% CI) 
 
 
 
50.7  
(0.26-0.38) 
 
 
2.4  
(0.26-0.38) 
 
 
56  
32.2% 
(25.3-39.7%) 
 
 
44  
25.2% 
(19.0-32.4%) 
 
 
8  
4.6% 
(2.0-8.9%) 
 
50.6  
(0.61-0.73) 
 
 
2.4  
(0.61-0.73) 
 
 
56  
75.6% 
(64.3-84.9%) 
 
 
29  
39.2% 
(28.0-51.2%) 
 
 
0 
0% 
(0-4.8%) 
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Univariable regression (Table 4.2) revealed that atrophic endometrium on hysteroscopy increased 
the odds of having insufficient sample on endometrial biopsy (OR 5.53, p=0.001) while endometrial 
thickness above 5mm on ultrasonography decreased the odds (OR 0.15, p=0.001). Increasing 
patient’s age (OR 1.04, p=0.001) and postmenopausal status (OR 4.49, p=0.001) were also 
associated with insufficiency of outpatient sampling in unadjusted analysis. When these variables 
were combined in a multivariable regression analysis to control for confounding, only endometrial 
atrophy on hysteroscopy (OR 4.79, p=0.04) and endometrial thickness above 5mm on 
ultrasonography (OR 0.19, p=0.001) remained significant in predicting an insufficient sample on 
outpatient endometrial biopsy. In a similar but separate multivariable model using endometrial 
thickness as a continuous variable we found that the odds of insufficient sample decreased with 
each 1mm increase in endometrial thickness (OR 0.88, 95% CI 0.78-0.99, p=0.03). 
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Table 4.2: Logistic regression analysis to determine the relationship between various factors 
associated with insufficient specimen on outpatient endometrial biopsy 
 
 Univariable Regression  Multivariable Regression* 
Risk Factor Odds Ratio 
(95% Confidence  
Intervals) 
P value 
 
 Odds Ratio 
(95% Confidence  
Intervals) 
P value 
 
 
Age 
(Years) 
 
 
1.04 
(1.01 - 1.06) 
 
0.001 
  
1.02  
(0.98 - 1.06) 
 
0.24 
 
Menopausal 
status 
(pre vs post) 
 
 
4.49  
(2.49 - 8.09) 
 
0.001 
  
1.92  
(0.66 – 5.61) 
 
0.23 
 
Ultrasonographic 
Endometrial 
thickness 
(5mm cut-off) 
 
0.15  
(0.06 – 0.37) 
 
0.001 
  
0.19  
(0.07 – 0.53) 
 
0.001 
 
Hysteroscopic 
endometrial 
thickness 
 
5.53  
(2.47 – 11.60) 
 
0.001 
  
4.79  
(1.05 - 21.91) 
 
0.04 
(atrophic vs non-
atrophic) 
 
     
*Multivariable logistic regression model with insufficient or sufficient sample on endometrial 
biopsy as the binary dependent variable and age, menopausal status, atrophic endometrium on 
hysteroscopy, and endometrial thickness on sonography as the independent variables. See methods 
for details. Parity (odds ratio 1.2, 95% confidence interval 0.9-1.5, β-coefficient 0.04, p=0.8) and 
use of hormone replacement therapy (odds ratio 1.6, 95% confidence interval 0.8-2.8, β-
coefficient –0.24, p=0.9) did not contribute to the model. There was no forward or backward 
selection or rejection process for the variables, they were forced into the analysis on clinical 
relevance.  
(Model deviance=98.46; Hosmer-Lemeshow goodness of fit test p=0.43 at 8DF) 
 
The Hosmer and Lemeshow Goodness-of-Fit Test below divides subjects into deciles based on 
predicted probabilities, then computes a chi-square from observed and expected frequencies. The 
p-value=0.43 is computed from the chi-square distribution with 8 degrees of freedom (8DF) and 
indicates that the logistic model is a good fit. That is, if the Hosmer and Lemeshow Goodness-of-
Fit test statistic is .05 or less, we reject the null hypothesis that there is no difference between the 
observed and predicted values of the dependent; if it is greater, as we want, we fail to reject the 
null hypothesis that there is no difference, implying that the model's estimates fit the data at an 
acceptable level. 
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4.4 Discussion  
4.4.1 Principal findings of the study: 
This study showed that insufficient sample on endometrial biopsy was associated with 
hysteroscopic finding of endometrial atrophy and ultrasonographically thin endometrium. 
Hysteroscopic finding of atrophy is subjective whereas measurement of endometrial thickness is 
objective. However, both of these tests independently influenced the odds of insufficient sample on 
outpatient biopsy making it more likely when there was evidence of endometrial atrophy. 
There was no association with the patient’s age, menopausal status, parity and use of hormone 
replacement therapy in multivariable analysis. 
 
4.4.2 Appraisal of quality of the study 
The type of controlled analysis used in this Chapter to delineate the significance of factors 
associated with insufficient specimen on outpatient endometrial biopsy has not been reported so far.  
 
The strength of this study and the credibility of its findings depend on the strength of the 
methodology. This is made clear by applying the Standard of Quality for Reporting Logistic 
Regression Models (Khan 1999) the objective of which is to to identify problems affecting the 
accuracy and interpretation of this approach to multivariable statistical analyses. Table 4.3. 
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Table 4.3: Application of the Standard of Quality for Reporting Logistic Regression Models  
 
Quality Feature Description of the Criteria  Compliance of 
This Study  
 
Did the model appear to be correct?   
• Research hypothesis 
 
It should be reported clearly  Yes 
• Reporting of the variable selection process It is adequate if it is based on consideration of the clinical importance 
of various factors 
 
Yes 
• Statistical significance threshold The threshold of statistical significance for inclusion or deletion of 
variables (e.g. in stepwise forward or backward regression) should be 
reported  
 
Yes  
• Conformity to linear gradient An attempt should be made to detect this problem, e.g. by comparison 
of the observed and the predicted values for the outcome over the 
ordinal zones or by an alternative analysis using cross-stratification 
 
Yes 
How well did the overall model work? 
 
  
• Testing for goodness-of-fit The accuracy with which the regression model describes the data 
should be assessed 
 
Yes 
How important was each of the independent variable? 
 
  
• Unit of measurement  The change in dependent variable associated with a unit change in the 
independent variable should be reported 
 
Yes 
• Coding of variables  A description of variables if they were on an interval, ordinal or binary 
scale should be provided 
 
Yes 
• Testing for interactions when the impact of one variable is dependent on the level of another 
variable, interactions between independent variables should be 
examined  
Yes 
 
4.4.3 Relation to other studies considering differences in quality and results 
Generally, an insufficient sample in women with abnormal uterine bleeding is not believed to be a 
cause for concern as failure to obtain an endometrial specimen from a devise correctly positioned 
within the uterine cavity is considered to be an assurance that no significant intrauterine pathology 
is present. There is still however controversy about the need for additional testing if outpatient 
endometrial biopsy is insufficient because of the lack of confidence that insufficient sample is 
benign. Some gynaecologists prefer to perform inpatient curettage under anaesthesia while others 
suggest that further tests may not be necessary (Ben Baruch et al., 1994).  
 
4.4.4 Practical implications for clinicians  
It would appear from this analysis that clinicians can be confident in reassuring women with 
insufficient sample on outpatient endometrial biopsy provided the hysteroscopic and sonographic 
endometrial assessment is consistent with endometrial atrophy. This means that inpatient dilatation 
and curettage can possibly be avoided in such women. However, in majority of settings the 
clinicians will only have the ultrasound scan result and perhaps not the outpatient hysteroscopy, in 
such a situation, the same advice still prove correct (i.e. to reassure and discharge women with 
insufficient endometial sample with thin endometrium on scan) without the need to book then for 
inpatient hysteroscopy and curettage. This is because p-value for the ultrasonographic endometrial 
thickness did not change on performing the multivariable regression analysis (p=0.001), as much as 
it did with hysteroscopic endometrial thickness (from p=0.001 to p=0.04). Table 4.2. Keeping in 
mind the need for usual precautions of reinvestigation on recurrence of symptoms. 
 
4.5.4 Implications on research 
• Insufficient sample may be regarded as a negative result in metaanalysis when outpatient 
biopsy is used as a gold standard. 
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• There is a suggestion that failure to obtain a sufficient endometrial sample in an outpatient 
biopsy may be due to the improper positioning of the Pipelle sampler devise within the 
uterine cavity. Therefore there is a need to design a randomised controlled trial looking at 
the success rate of obtaining sufficient sample with or without the use of ultrasound scan at 
the time of sampling to monitor for the correct positioning of the Pipelle sampler devise.  
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CHAPTER 5 
 
THE RISK OF PREMALIGNANT AND MALIGNANT PATHOLOGY IN 
ENDOMETRIAL POLYPS 
 
5.1 Introduction 
Abnormal uterine bleeding, accounting for up to 20% of outpatient visits, is one of the most 
common gynaecological problems (Ben Yehuda et al., 1998). In women over the age of 40 years, 
the management requires prompt diagnosis to exclude intrauterine pathology. Traditionally, 
dilatation and curettage was performed to exclude endometrial pathology. However, as this is a 
blind procedure, endometrial polyps have been missed in 50-85% of cases (Maja 1996; Maja Jr 
1996). Currently outpatient evaluation is preferred using imaging techniques including 
hysteroscopy and ultrasonography (Bakour 1999; Cicinelli 1993; Gimpleson 1998; Towbin 1996). 
These new methods of evaluation have revealed that uterine polyps are common findings, ranging 
in rate from 16 to 34% (Gimpleson RJ 1998; Loffer 1989; Saidi, Sadler, Theis, Akright, Farhart, 
Villanueva 1997; Towbin NA 1996; Valle 1981). The aetiology and pathogenesis of endometrial 
polyps are not fully understood but polyps are believed to be a risk factor for endometrial cancer 
(Maja Jr H 1996). However, this issue has seldom been substantiated in a controlled study. With the 
knowledge that only a few studies have looked at the pathological significance of endometrial 
polyps (Maja 1996; Maja Jr 1996), this study was conducted to comprehensively address the 
following research question:  
What is the risk of premalignant and malignant pathology among endometrial polyps?  
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5.2 Methods 
A cohort of 248 consecutive patients was prospectively evaluated for abnormal uterine bleeding in a 
rapid access One-stop outpatient clinic from November 1996 to December 1997 (Bakour 1999). 
Ethical considerations are discussed in Section 2.2.  
 
The One-stop clinic was conducted by a consultant or by a senior minimal access surgery trainee. 
After consultation, counselling and physical examination, outpatient mini-hysteroscopy, and Pipelle 
endometrial sampling were performed. Inpatient hysteroscopy and curettage under general 
anaesthesia were performed if the hysteroscopic view was poor or if the biopsy was not obtained in 
outpatient setting. Pelvic transvaginal ultrasonography was performed in some patients using an 
endovaginal 6.5 MHz transducer of a portable scanner (Hitachi Sumi, Japan) (Bakour 1999). 
Outpatient hysteroscopy was performed using a 1.2mm micro-hysteroscope in 2.5mm outer rigid 
sheath (Karl Storz, Tuttlingen, Germany) with normal saline solution as the distending solution. 
Outpatient endometrial biopsies were performed using Pipelle sampling (Laboratoire CCD, Paris, 
France) (Stovall 1991). The polyps were all removed under general anaesthesia by avulsion with a 
polypectomy forceps and subjected to histological assessment. Histological diagnosis was classified 
as benign (hormonal, exogenous hormonal effect, simple polyp), hyperplasia (simple, complex or 
atypical) or carcinoma. Some reviewers would not agree to include simple hyperplasia cases in the 
analysis on the categorisation that simple hyperplasia is not a premalignant lesion. However, in my 
opinion, simple hyperplasia is still a pathological histology and clinically if symptomatic would 
need treatment.   
 
To determine the magnitude of malignant potential among polyps, the pathological findings in 
polyps (cases) were compared with non-polypoidal specimens (controls) using Fisher’s Exact Test. 
The risk of malignancy among polyps with estrogenic exposure was also examined. 
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5.3 Results 
Of the 248 patients, 62 (25%) had endometrial polyps on hysteroscopy. The mean age was 53.7 
(95% CI 49.6-57.8), the mean parity was 2.2 (95% CI 1.8-2.6). Of the 62 women with polyps, 30 
(48.4%) were postmenopausal, 19 (30.6%) women were on hormone replacement therapy (HRT) 
and 10 (16.1%) were receiving tamoxifen. Histologically, 53/62 (85.5%) polyps were benign, 6/62 
(9.6%) had hyperplasia (two simples and four complex/atypical), and 3/62 (4.8%) polyps were 
malignant.  
 
Overall 24/248 patients had hyperplasia or cancer on histology in this series. Of these, nine cases 
were found in polyps and 15 were found in women without polyps (9/62 vs 15/186, 14.5% vs 
8.1%). As shown in Table 5.1, hyperplasia was more frequent among women with polyps than in 
women without (9.6% vs 4.8%, OR= 2.1, 90% CI 0.85-5.2). This result was not significant at the 
traditional cut-off p-value as the p value was 0.16. However, it shows a significant trend towards an 
association between hyperplasia and polyps. There was no such difference for cancer (3.4% vs 
2.8%, OR= 1.5, 90% CI 0.46-5.0, p=0.5).  
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Table 5.1: Endometrial hyperplasia and cancer in women with endometrial polyps and those 
without 
 
Histology* Without 
Polyp 
N=186 
 
With 
Polyps 
N=62 
 
P Value# 
 
 
Odd Ratio 
90% CI 
 
Hyperplasia 
-Simple 
-Complex/Atypical 
 
9 (4.8%) 
3 (1.6%) 
6 (3.2%) 
 
 
6 (9.7%) 
2 (3.2%) 
4 (6.5%) 
 
 
0.16 
 
2.1 
(0.85-5.2) 
Carcinoma 6 (3.2%) 3 (4.8%) 0.5 1.5 
(0.46-5.0) 
 
*Histologic diagnoses are classified as benign (including hormonal effect), hyperplasia 
(simple, complex, or atypical) or cancer based on the pathology report. 
# P value for Chi- square Test comparing the effect of polyps on the occurrence of 
hyperplasia or cancer on histopathology. 
 
 59
Separate analysis (not included in this thesis) carried out among the same cohort of the 248 patients, 
showed a high incidence of polyps in those taking tamoxifen (tamoxifen group) with approximately  
36% of these polyps showing abnormal changes. This background prompted the examination of the 
relationship between estrogenic exposure and risk of malignancy among polyps. This further 
analysis revealed that amongst the 19 HRT users one patient had complex hyperplasia and one had 
atypical hyperplasia, while amongst the 10 tamoxifen users two had complex/atypical hyperplasia. 
No cancer cases were found (Table 5.2). Compared to no estrogenic exposure, HRT and tamoxifen 
exposure increased the odds of having polyps with hyperplasia or cancer but this result was not 
statistically significant (OR=1.5, 95% CI 0.36-6.26, p=0.5). 
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Table 5.2: Histology of endometrial polyps and estrogenic exposure to hormone replacement 
therapy or tamoxifen 
 
Estrogenic exposure Histology*Of 
Endometrial Polyps 
HRT+ Tamoxifen 
No exposure P value# 
Benign    
17           
 
7 
 
29 
 
 
 
Hyperplasia 
- Simple 
 
 
0 
 
 
1 
 
 
1 
 
 
0.5# 
-Complex/atypical 2 2 0  
 
 
Cancer 
 
            0 
 
            0 
 
            3 
 
 
 
 
* Histologic diagnoses are classified as benign (including hormonal effect), hyperplasia (simple, 
complex, or atypical) or cancer based on the pathology report. 
+ HRT = hormone replacement therapy 
# P value for Fisher Exact Test comparing the effect of estrogenic exposure (HRT and tamoxifen) 
vs non-exposure on the occurrence of benign vs hyperplasia/cancer. (OR=1.5, 95% CI 0.36-6.26, 
p=0.5). 
 
 
 61
5.4 Discussion  
5.4.1 Principal findings of the study  
The principal finding of this study was that in polyps the rate of abnormal histology was 
approximately double that in the non-polyp group. The study concluded that hyperplasia was, but 
cancer was not, more common in women with endometrial polyps than in those without. 
 
5.4.2 Appraisal of quality of the study  
The credibility of these findings depends on the strength of the methodology.  Polyps were 
identified using high quality imaging with microfibreoptic hysteroscopes. Hysteroscopy was 
considered to be the gold standard for detecting endometrial polyps because it provided direct 
visualisation of the endometrial cavity and polyps in it (Bakour 1999; Haller 1996; Loffer 1989; 
Saidi 1997; Valle 1981). Hence, any chance of misclassification of risk category was limited to a 
minimum. As far as the outcome variable of the index study is concerned, the nature of pathology 
was confirmed in all patients by histological examination of specimens obtained from the 
endometrial cavity. As histology was the gold standard for diagnosing hyperplasia or cancer, the 
risk of misclassification of outcome was also eliminated. In this manner, the methodology was 
robust to produce a credible estimate of the malignant potential associated with endometrial polyps. 
 
The association of endometrial polyps with premalignant and malignant pathology has not been 
presented before in a control analysis. Its conclusion may, however, be challenged on the basis of 
variation in p-values (p value= 0.16, OR= 2.1). This challenge would be strongly rebutted on the 
basis that the significance level used in hypothesis testing is based on an arbitrary dichotomy and it 
is not as informative as the CI (Brennan 1994).  In fact, Sterne et al., (2001) have recommended that 
p values should not be used in observational studies and 90% confidence intervals around odds 
ratios should be readily accepted. However, the results showed a significant trend towards an 
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association between hyperplasia and polyps. Furthermore, the true values are more likely to lie near 
the centre of the interval than at the extremes i.e. the true point estimate is more likely to be >1.0.   
 
5.4.3 Relation to other studies considering differences in quality and results 
It appears that the evidence is suggestive of a clinically significant relationship between polyps and 
hyperplasia that merits consideration. This trend has been confirmed in an independent data set 
collected in the same One -Stop clinic subsequent to this paper involving 790 women.  Hyperplasia 
was found more frequent in women with polyps than in those without (14/95 vs 38/695 or 14.73% 
vs 5.46%, p=0.0006, OR=2.98, 90% CI 1.72-5.17) while there was no significant difference with 
regard cancer (1/95 vs 19/695 or 1.05% vs 2.73%, p=0.33, OR=0.37, 90% CI 0.07-2.06) (personal 
communication). 
 
Moreover, on examining the consistency of the findings of this study with that of other literature, 
there was satisfaction that the 25% rate of endometrial polyps was comparable with the 16-34% 
range of rates quoted by other authors (Gimpleson RJ 1998; Loffer 1989; Saidi, Sadler, Theis, 
Akright, Farhart, Villanueva 1997; Towbin NA 1996; Valle 1981). The increasing use of HRT in 
postmenopausal women and adjuvant therapy (tamoxifen) in women with breast cancer (Maja 1996; 
Maja Jr 1996) was believed to be associated with endometrial abnormalities. HRT may induce 
polyps or it may simply stimulate pre-existing polyps due to the effect of estrogens. Tamoxifen 
administration as adjuvant therapy for breast cancer, confers a survival benefit (Cheng 1997; 
Exacoustos 1995; Ismail 1996; Maja 1996; Maja Jr 1996). However, the drug’s weak estrogen 
effect may lead to the development of endometrial proliferative abnormalities ranging from 
hyperplasia to invasive cancer, with endometrial polyps occupying the intermediate ground (Cheng 
1997; Cohen 1993; Hardell 1988; Lahti 1993). This background prompted the examination of the 
relationship between estrogenic exposure and the risk of malignancy among polyps. It was found  
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that the odds of hyperplasia and cancer were high with estrogenic exposure (Table 5.2). Although 
the result from Table 5.2 did not reach statistical significance, it supports the policy that 
symptomatic women on HRT and tamoxifen should be investigated promptly (Cheng 1997; Cohen 
1993; Hardell 1988; Lahti 1993; Powles 1998) 
 
5.4.4 Practical implications for clinicians 
The diagnosis of uterine polyps is becoming more common than previously assumed. This study 
indicates that the detection of polyps should be taken seriously. The management of polyps is at 
present varied but the findings of this study reinforce the need for their formal removal followed by 
histological assessment.  
 
5.4.5 Implications on research 
• This study revealed that in abnormal uterine bleeding, hyperplasia was more common in 
women with endometrial polyps than in those without. Therefore the diagnosis, prognosis 
and management of polyps require further evaluation in larger study in order to avoid the 
risk of type-II error (where there is in fact a difference between the two groups but the study 
failed to reveal it as it was not powered enough).  
• Randomised trials are required to address the effectiveness and cost-effectiveness of various 
methods of polypectomy. 
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CHAPTER 6 
 
RISK FACTORS ASSOCIATED WITH ENDOMETRIAL POLYPS IN 
ABNORMAL UTERINE BLEEDING 
 
6.1      Introduction 
Endometrial polyps are a common problem in women with abnormal uterine bleeding accounting 
for up to 25% of such cases (Bakour et al., 2000). Hormone replacement therapy (Maja Jr 1996) 
(with or without progestogen) and tamoxifen treatment (Cheng 1997) have been associated with the 
development of endometrial polyps, presumably mediated through agonistic estrogenic effects 
(Reslova et al., 1999). However, polyps are also frequently seen in postmenopausal women who are 
not exposed to these estrogenic agents. In the relationship between exposure to estrogenic agents 
and occurrence of polyps, the confounding effects of other factors have not been taken into account. 
Therefore, a controlled analysis was conducted to answer the following research question:  
What is the significance of various risk factors (age, parity, menopausal status, hormone 
replacement therapy, and tamoxifen) in the development of endometrial polyps?  
By evaluating the relationship of hormone replacement therapy and tamoxifen treatment with the 
development of endometrial polyps, adjusting for the confounding effects of other factors such as 
age, parity and menopausal status. 
 
6.2 Methods 
To perform this analysis I used a database of 248 consecutive patients evaluated for abnormal 
uterine bleeding in the One-stop from November 1996 to December 1997 (Bakour 1999). Ethical 
considerations were discussed in Section 2.2.  
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Patients were referred to the service from gynaecology outpatient clinics or directly from general 
practice for the investigation of a wide spectrum of abnormal uterine bleeding including: 
menorrhagia, irregular menstrual loss, postmenopausal bleeding, unscheduled bleeding on 
tamoxifen, and unscheduled bleeding on combined hormone replacement therapy either sequential 
or continuous.  
 
Endometrial polyps were diagnosed using outpatient hysteroscopy performed with a 1.2 mm micro-
hysteroscope in a 2.5mm rigid sheath (Karl Storz, Tuttlingen, Germany) with normal saline solution 
as the distension medium. Direct visualization using hysteroscopy is generally regarded as the ‘gold 
standard’ for the diagnosis of polyps (Loffer 1989; Pal et al., 1997). Submucous fibroid polyps and 
thickened polypoidal endometrium were not considered as endometrial polyps. For statistical 
analysis, each patient was regarded as a single unit of analysis whether with single, multiple, small 
or large polyps. The histological nature of the polyp was confirmed in all patients by performing 
inpatient polypectomy. 
 
To explore whether tamoxifen or hormone replacement therapy were associated with polyps while 
adjusting for the effects of age, parity and menopausal status, a multivariable logistic regression 
model was built with the occurrence of polyps as the binary outcome variable. The primary null 
hypothesis was, in terms of the logistic model “the value of the beta coefficient for the exposure to 
estrogenic therapy is zero or its exponent is 1.0”. To obtain a valid estimate of the association 
between exposure to estrogenic therapy (hormone replacement therapy and tamoxifen) and 
occurrence of polyps, the analysis was controlled for the confounding effects of age, parity and 
menopausal status by including them in the multivariable logistic regression analysis. The model 
building process was undertaken according to published guidelines (Khan 1999). The model that 
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best predicted the occurrence of polyps with the lowest deviance and highest goodness of fit was 
selected.  
 
6.3 Results 
Sixty-two cases with endometrial polyps were identified by hysteroscopy. The characteristics of the 
women attending the One-stop clinic are shown in Table 6.1. This table provides a simple 
comparison between women with polyps (cases) and those without polyps (controls) for age, parity, 
menopausal status, tamoxifen use and hormone replacement therapy. 
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Table 6.1: Comparison of women with and without polyps diagnosed in One-stop clinic 
 
Patients’ 
Characteristics 
With Polyp 
      N=62 
 
Without Polyp 
N=186 
Age - years 
Mean (95% CI) 
53.7 (49.6-57.8) 49.6 (47.5-51.8) 
   
Parity 
Mean (95% CI) 
2.2 (1.8-2.6) 2.5 (2.3-2.7) 
   
Menopausal Status 
Postmenopausal 
31 (50%) 81 (43.5%) 
Premenopausal 
n (%) 
31 (50%) 105 (56.5%) 
   
Use of Hormone Replacement Therapy 
Yes 19 (30.6%) 54 (29%) 
No 
n (%) 
43 (69.4%) 132 (71%) 
   
Tamoxifen Treatment 
Yes 10 (16.1%) 5 (2.7%) 
No 
n (%) 
52 (83.9%) 181 (97.3%) 
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Univariable regression (unadjusted analysis) revealed that in this group of women undergoing 
investigation for abnormal uterine bleeding, tamoxifen treatment increased the odds of having an 
endometrial polyp (OR=6.96, p=0.0007). The effect of hormone replacement therapy and 
menopausal status did not statistically significantly increase the odds of having a polyp (OR=1.08, 
p=0.80 and 1.25, p=0.44 respectively). Multivariable regression analysis adjusting for the 
confounding effects of age, parity and menopausal status showed that the effect of tamoxifen 
treatment on occurrence of polyps continued to be significant (adjusted OR 11.21, p=0.0009), but 
the use of hormone replacement therapy did not have a significant association (adjusted OR=1.48, 
p=0.32). Table 6.2.  
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Table 6.2: Logistic regression analysis to determine the significance of factors associated with 
endometrial polyps. 
 
 Univariable Regression  Multivariable Regression* 
Risk Factor Odds Ratio 
(95% Confidence  
Intervals) 
P-value 
 
 Odds Ratio 
(95% Confidence  
Intervals) 
P-value 
 
 
Age 
(1 year 
increment) 
 
1.02  
(1.00 - 1.04) 
 
0.07 
  
1.00  
(0.98 - 1.03) 
 
0.80 
 
Parity 
(1 unit 
increment) 
 
0.86  
(0.69 - 1.08) 
 
0.20 
  
0.83  
(0.64 - 1.07) 
 
0.15 
 
Menopause 
(Post / Pre) 
 
 
1.25  
(0.70 – 2.24) 
 
0.44 
  
0.95  
(0.44 - 2.04) 
 
0.89 
 
Hormone 
Replacement 
Therapy 
(Yes / No) 
 
1.08 
(0.58 - 2.02) 
 
0.80 
  
1.48  
(0.68 - 3.20) 
 
0.32 
 
Tamoxifen 
Therapy 
(Yes / No) 
 
 
6.96  
(2.28 - 21.26) 
 
 
0.0007 
  
11.21  
(2.70 – 46.46) 
 
0.0009 
*Multivariable logistic regression model with presence or absence of polyp as the binary 
outcome variable and age, parity, menopausal status, hormone replacement therapy and 
tamoxifen treatment as predictor variables. See methods for details. There was no forward or 
backward selection or rejection process for the variables, they were forced into the analysis on 
clinical relevance.  
 (Model deviance=98.46; Hosmer-Lemeshow goodness of fit test p=0.43 at 8DF) 
 
The Hosmer and Lemeshow Goodness-of-Fit Test below divides subjects into deciles based on 
predicted probabilities, then computes a chi-square from observed and expected frequencies. The p-
value=0.43 is computed from the chi-square distribution with 8 degrees of freedom (8DF) and 
indicates that the logistic model is a good fit. That is, if the Hosmer and Lemeshow Goodness-of-Fit 
test statistic is .05 or less, we reject the null hypothesis that there is no difference between the 
observed and predicted values of the dependent; if it is greater, as we want, we fail to reject the null 
hypothesis that there is no difference, implying that the model's estimates fit the data at an 
acceptable level.
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6.4 Discussion 
 
6.4.1 The principle findings of this study 
This study confirmed that tamoxifen was associated with endometrial polyps. However, it rejected 
the hypothesis that hormone replacement therapy was a risk factor for endometrial polyps. 
 
6.4.2 Appraisal of quality of the study  
The strength of this study and the credibility of its findings depend on the strength of the 
methodology. This is made clear by applying the Standard of Quality for Reporting Logistic 
Regression Models (Khan 1999) the objective of which is to to identify problems affecting the 
accuracy and interpretation of this approach to multivariable statistical analyses. Table 6.3. 
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Table 6.3: Application of the Standard of Quality for Reporting Logistic Regression Models  
 
Quality Feature Description of the Criteria  Compliance of 
This Study  
 
Did the model appear to be correct?   
• Research hypothesis 
 
It should be reported clearly  Yes 
• Reporting of the variable selection process It is adequate if it is based on consideration of the clinical importance 
of various factors 
 
Yes 
• Statistical significance threshold The threshold of statistical significance for inclusion or deletion of 
variables (e.g. in stepwise forward or backward regression) should be 
reported  
 
Yes  
• Conformity to linear gradient An attempt should be made to detect this problem, e.g. by comparison 
of the observed and the predicted values for the outcome over the 
ordinal zones or by an alternative analysis using cross-stratification 
 
Yes 
How well did the overall model work? 
 
  
• Testing for goodness-of-fit The accuracy with which the regression model describes the data 
should be assessed 
 
Yes 
How important was each of the independent variable? 
 
  
• Unit of measurement  The change in dependent variable associated with a unit change in the 
independent variable should be reported 
 
Yes 
• Coding of variables  A description of variables if they were on an interval, ordinal or binary 
scale should be provided 
 
Yes 
• Testing for interactions when the impact of one variable is dependent on the level of another 
variable, interactions between independent variables should be 
examined 
  
Yes 
 
6.4.3 Relation to other studies considering differences in quality and results 
While the aetiology and pathogenesis of endometrial polyps are not fully understood, it is generally 
believed that hormone replacement therapy (with or without progestogen) is a factor that may 
induce endometrial polyps (Maja Jr 1996). The results of this study using robust analysis do not 
support this notion.  
 
When evaluating the association between hormone replacement therapy use and occurrence of 
polyps, multivariable logistic regression analysis was used in this study to adjust for the 
confounding effect of several variables. For example, inclusion of menopausal status in the model 
produced a stratified analysis of the effect of hormone replacement therapy on polyps in 
premenopausal and postmenopausal women, and included an adjustment for this confounding 
variable. In this way, the odd ratios (and their p-values) demonstrated the lack of an association 
between hormone replacement therapy and polyps in light of the variation in menopausal status, 
age, parity, and tamoxifen use in this sample. In addition, these results confirmed that tamoxifen 
treatment was a significant risk factor associated with endometrial polyps. 
 
6.4.4 Practical implications for clinicians  
There are numerous recognized reasons for long-term non-compliance use of hormone replacement 
therapy (Coope 1992), such as irregular bleeding and/or fear of increased risk of breast cancer. It 
appeared from this study that the risk of hormone replacement therapy inducing endometrial polyps 
should not be one of these reasons.  
 
Clinicians have to be careful in interpreting these findings since the study population was a selected 
group of women who were referred to the special clinic for the investigation of abnormal uterine 
bleeding. This means that the generalization of the results is limited to symptomatic women.  
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6.4.5 Implications on research 
It appeared from this study that the risk of hormone replacement therapy inducing endometrial 
polyps should not be one of the reasons for long-term non-compliance use of hormone replacement 
therapy. It is important to confirm the lack of the association between hormone replacement therapy 
and polyps in a larger study to inform the debate for and against the use of hormone replacement 
therapy. 
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CHAPTER 7 
 
FEASIBILITY OF MULTIVARIABLE ANALYSIS TO EVALUATE 
COMBINATIONS OF TESTS IN THE DIAGNOSIS OF ENDOMETRIAL 
DISEASE 
 
7.1 INTRODUCTION 
Accurate diagnosis is a critical part of the clinical process because it allows optimal management 
strategies to be employed. Incorrect diagnoses may put patients at risk and waste limited resources 
(Fineberg 1979; Reid 1995). Medical diagnosis is usually based on information acquired from a 
variety of components, which make up the clinical process (i.e. history, examination and tests). The 
need to rigorously assess the accuracy of the clinical history and examination has been highlighted 
(McAlister 1999), but in our view the need is to integrate this part of the clinical process with 
diagnostic tests. The whole clinical process should be borne in mind when conducting research to 
evaluate a diagnostic strategy and when implementing new tests into clinical practice. Diagnostic 
accuracy in studies evaluating tests in isolation from the rest of the clinical context does not 
necessarily indicate how useful the test will be in practice (Begg 1989; Khan 2001; Moons et al., 
1996). To determine this, evaluation within the context of contemporary clinical practice is 
essential. This is because the information generated by a diagnostic test may have already been 
obtained from the patient’s history and physical examination, which have taken place earlier in the 
clinical process. The true clinical value of a test lies in the added information over and above what 
was already known from the history and examination. 
 
A stepwise multivariable approach in the evaluation of diagnostic tests (Khan 1999) allows the 
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clinical context, in which the test will be used, to be accounted for. This study develops such an 
approach and explores its application in the diagnosis of endometrial disease (hyperplasia or cancer) 
in the context of an outpatient rapid access clinic. In the same unit systematic reviews (Clark 2002a; 
Clark 2002b; Clark et al., 2001; Gupta 2002) were conducted addressing the diagnostic accuracy of 
tests used in predicting endometrial disease in this setting (ultrasound, hysteroscopy and biopsy), 
which included over 100 primary studies, none of which used stepwise multivariable approaches. 
Therefore, the research question raised in this chapter was:  
What is the feasibility of multivariable analysis to evaluate the added value of combinations of 
diagnostic tests in the diagnosis of endometrial disease in routine practice where some diagnostic 
information is already available from clinical history? 
  
7.2 Methods 
In an outpatient One-stop clinic for investigation of abnormal uterine bleeding, patients’ age at 
presentation, menopausal status and use of hormone replacement therapy are recorded. The ethical 
considerations are covered in Section 2.2. Patients then undergo further investigation with a 
combination of pelvic ultrasound scan and outpatient hysteroscopy. Data collected from 248 
consecutive patients investigated in our one-stop clinic for abnormal uterine bleeding from 
November 1996 to December 1997 was used to develop a model to determine the added value of 
ultrasonography and hysteroscopy. 
 
Univariable analyses of the tests employed in this data set have been published Previously (Bakour 
1999a; Bakour 1999b). Pelvic transvaginal ultrasonography was performed using an endovaginal 
6.5 MHz transducer of a portable scanner (Hitachi Sumi, Japan). Double layer endometrial 
thickness was measured in mm, and endometrial thickness of 5mm was used as a cut-off, based on 
the findings of a recent review (Smith-Bindman et al., 1998). Mini-hysteroscopy was performed 
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using a 1.2mm micro-hysteroscope with 2.5mm rigid sheath (Karl Storz, Tuttlingen, Germany). By 
applying simple pressure with the hysteroscope, the depth of mucosa was assessed; hysteroscopic 
features of smooth non-vascular endometrium were considered as normal hysteroscopy while 
features of increased endometrial thickness, abnormal vascularisation, irregular friable polypoid 
formations with necrosis or bleeding, were considered suspicious lesions (Ben Yehuda et al.,1998; 
Cicinelli 1993; Uno et al., 1995). The gold standard was based on histological diagnoses. These 
diagnoses were classified as either negative (secretory/proliferative endometrium and benign 
endometrial polyps), or positive (endometrial hyperplasia and carcinoma), because the main aim of 
investigations for abnormal uterine bleeding is to exclude serious intrauterine pathology, primarily 
endometrial cancer and hyperplasia. The secondary aim is to stop the bleeding which is the real 
symptomatic problem to the patient.  
 
Histological samples were provided by outpatient endometrial biopsy (Laboratoire CCD, Paris, 
France), dilatation and curettage (D&C) and hysterectomy specimens. In patients where outpatient 
biopsy was inadequate, inpatient sampling was performed. All patients were followed up for a 
minimum of 6 months and recurrent symptoms were used as an indication for reassessment. 
Although outpatient biopsy is a simple and inexpensive diagnostic test, there are concerns 
surrounding the non-representative nature of blind endometrial biopsy (Guido 1995; Rodriguez 
1993) and this is the rationale for employing hysteroscopic or ultrasound imaging. However, in this 
study, no erroneous diagnoses on outpatient biopsy were identified from hysterectomy specimens, 
D&C or following reinvestigation of symptoms at 6 months follow up and so its use as the  
diagnostic reference standard appears to be justified. 
 
Logistic regression analysis (Khan 1999; Norman 1994) was used to delineate the predictive values 
of the historical features age, menopausal status and hormone replacement therapy use, and results 
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from ultrasound and hysteroscopy (independent variables) on endometrial hyperplasia or cancer 
(binary dependent variable).  
 
Initially univariable analysis was performed followed by multivariable modeling. Four diagnostic 
models were produced by multivariable analysis, which included historical features alone, historical 
features plus ultrasonography, historical features plus hysteroscopy and historical features plus 
ultrasonography and hysteroscopy. Postmenopausal status, use of hormone replacement therapy, 
ultrasonic endometrial thickness greater than 5mm and suspicious findings on hysteroscopy were all 
considered positive results. Age was split into six categories; less than or equal to 30 years, 31-40 
years, 41-50 years, 51-60 years, 61-70 years and over 70 years. Increasing age was considered more 
likely to be associated with endometrial pathology. 
 
The objective of this study was to develop an analytical approach. To allow the building of 
multivariable models using this small data set, cases of endometrial cancer and hyperplasia had to 
be used combined to increase the number of outcome events and any missing data were imputed 
(Norman 1994) (see results). Using a univariable approach for each diagnostic (independent) 
variable, the diagnostic odds ratio (dOR) was calculated where values >1.0 showed an increased 
level of accuracy. The dOR represents a ratio of the positive and negative likelihood ratios and it 
can be mathematically summarized as:  
dOR = [sensitivity /(1-specificity)] / [ specificity /(1-sensitivity)]. 
After the univariable analysis, four multivariable logistic regression models were then built 
(Concato 1993; Khan 1999; Norman 1994) using BMDP statistical software release (Concato 1993; 
Norman 1994) (BMDP Statistical Software Inc., Los Angeles, CA). These models were built to 
allow the statistical approach to mimic the clinical process. The first model built was to provide a 
valid estimate of the combined predictive value of the historical variables (i.e. age, menopausal 
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state and use of hormone replacement therapy). The other three models determined the combined 
predictive added value of history and tests (ultrasonography or hysteroscopy and ultrasound or 
hysteroscopy combined). This mirrors the real clinical situation where historical information is 
acquired prior to undertaking investigation with ultrasound scan or hysteroscopy. 
 
The predictive value of each model was summarized by plotting the estimates of sensitivity (true 
positive rates) against 1- specificity (false positive rates) to develop a receiver operating 
characteristic (ROC) curve that characterizes the performance of the test (Hanley 1982; Swets  
1988). This is a commonly used approach in both primary and secondary research for evaluating 
diagnostic accuracy of tests (Irwig 1995; Linnet 1988; Swets 1988; Walter 1999). The ROC curves 
can be readily generated from logistic regression modelling and this type of approach has been used 
in tests with multiple covariates (Tosteson 1994). The area under the curve (ROC area) determines 
the accuracy with which the test diagnoses the condition of interest. A ROC area greater than 0.5 
suggests some degree of test accuracy, with higher accuracy suggested by an ROC area closer to 1.0 
(representing perfect test accuracy). The ROC areas for each model were compared. 
 
The hypothesis that the study designed to test was about the improvement in prediction achieved by 
adding tests to the history. The chi-square test was used to test for statistically significant 
improvement between models and was computed from the log of the ratio of the current versus the 
previous likelihood function values. A small p-value indicated a significant change in prediction. 
 
7.3 Results 
The mean age of the 248 women included in this study was 50 years (range 23 to 94 years) and 112 
(45%) were postmenopausal. Forty- five women (18%) were under 40 years of age and 73 women 
(30%) were taking hormone replacement therapy. Twenty-three women (9%) had endometrial 
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disease (cancer/hyperplasia) on histopathological assessment. All cases of cancer detected were in 
women over 40 years of age as were the majority of endometrial hyperplasia (85%). Data for 
hysteroscopy and outpatient biopsy were complete, but 10% of the total data were missing for the 
other variables and these data were imputed (Norman GR 1994). There were 14 false-positive and 
17 false-negative diagnoses with hysteroscopy and 121 false-positive and seven false-negative 
diagnoses with ultrasound measurement of endometrial thickness. 
 
Table 7.1 shows the results of the univariable and multivariable approaches to summarize the 
diagnostic value of history and tests. The historical features (age, postmenopausal bleeding and use 
of hormone replacement therapy) were all significant predictors of endometrial hyperplasia or 
cancer using a univariable approach. Similarly, ultrasonography and hysteroscopy were also 
significant predictors. These univariable evaluations were then combined in a stepwise fashion in 
keeping with the clinical context described above. 
 
The predictive ability of all the historical features combined measured by the ROC area for the 
model including historical features was 0.78. The addition of ultrasonography to historical features 
significantly increased the ROC area (0.78 versus 0.82, χ2 for improvement = 5.6, p=0.02) (Figure 
7.1). Similarly, the addition of hysteroscopy to historical features significantly increased the ROC 
area (0.78 versus 0.81, χ2 for improvement = 7.1, p=0.008) (Figure 7.2). The addition of both 
ultrasonography and hysteroscopy increased the ROC area to 0.84. This represented significantly 
improved predictive ability from the clinical history plus ultrasonography model (0.82 versus 0.84, 
χ2 for improvement = 6.9, p=0.009) and from the clinical history + hysteroscopy model (0.81 versus 
0.84, χ2 for improvement = 5.4, p=0.02) (Figures 7.1 and 7.2).
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Table 7.1:  Results of univariable and stepwise multivariable analyses to assess the ability of patient history, hysteroscopy and ultrasonography to predict the presence of endometrial hyperplasia or cancer in 248 
women with abnormal uterine bleeding.  
 
 
dOR = [sensitivity /(1-specificity)] / [ specificity /(1-sensitivity)] 
* dOR for age represent the odds ratio for each category using the category < 30 years as the reference category. 
1. improvement in prediction p = 0.008 
2. improvement in prediction p = 0.02 
3. improvement in prediction p = 0.02 (from hysteroscopy model) and p = 0.009 (from ultrasound model) 
Goodness of fit: As the objective of the exercise was to test for the feasibility of such a model and no clinical implications were recommended, the goodness of fit for the 
various models were not given. 
 
 
Figure 7.1:  Improvement in diagnostic accuracy achieved by addition of tests to the information provided by 
Patient history. Area under receiver operating characteristic (ROC) curves of the diagnostic models based on  
Patient history, patient history plus endometrial thickness measured by ultrasound scan and patient history plus 
ultrasound scan and hysteroscopy 
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Figure 7.2: Improvement in diagnostic accuracy achieved by addition of tests to the information provided by 
patient history. Area under receiver operating characteristic (ROC) curves of the diagnostic models based on 
patient history, patient history plus hysteroscopy and patient history plus hysteroscopy and endometrial 
thickness measured by ultrasound scan 
 
 
 
 
 83
7.4 Discussion 
7.1.1 Principal findings of the study  
This study shows that multivariable analysis for evaluation of combinations of tests is feasible. 
In this study, univariable analyses of the various diagnostic variables had suggested potential value 
in history and tests for predicting serious endometrial disease (hyperplasia or cancer) in women 
with abnormal uterine bleeding. Multivariable analyses showed that both ultrasonography and 
hysteroscopy increased the prediction of serious endometrial pathology above that predicted from 
clinical history alone. The use of both ultrasonography and hysteroscopy together marginally (but 
statistically significantly) increased the predictive ability further.  
 
7.4.2 Appraisal of quality of the study  
Diagnostic tests are evaluated for accuracy in relation to a reference standard, often in isolation 
from the clinical context in which they will be used. Estimates of diagnostic accuracy derived in 
this way can lead to erroneous inferences and may artificially inflate the value of diagnostic tests 
(Begg 1989; Moons 1996). This study shows that to avoid misleading clinical inferences 
multivariable regression models can be constructed to reflect clinical practice. 
 
This type of multivariable analysis to delineate the significance of diagnostic variables is important 
in facilitating meaningful clinical interpretation of tests. This is because it allows the added value of 
tests to be determined in light of information already available to the clinician from the history, 
thereby reflecting the real clinical situation. If, however, multivariable regression analysis does not 
reveal any additional value of a diagnostic intervention in predicting a particular disease, then it 
should not be used in routine clinical practice. 
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The clinical performance of a test can be described in terms of diagnostic accuracy, or the ability to 
correctly classify subjects into clinically relevant subgroups. ROC plots provide a pure index of 
accuracy by demonstrating the limits of a test's ability to discriminate between alternative states of 
health over the complete spectrum of operating conditions. Furthermore, ROC plots occupy a 
central or unifying position in the process of assessing and using diagnostic tools (Zweig and 
Campbell 1993). Quantitative ROC analysis was employed to develop a multivariable approach to 
determine the added value of hysteroscopy and ultrasonography tests in routine practice where 
some diagnostic information is already available from the clinical history.  
 
The strength of this study and the credibility of its findings depend on the strength of the 
methodology. This is made clear by applying the Standard of Quality for Reporting Logistic 
Regression Models (Khan 1999) the objective of which is to to identify problems affecting the 
accuracy and interpretation of this approach to multivariable statistical analyses. Table 7.2. 
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Table 7.2: Application of the Standard of Quality for Reporting Logistic Regression Models  
 
Quality Feature Description of the Criteria  Compliance of 
This Study  
 
Did the model appear to be correct?   
• Research hypothesis 
 
It should be reported clearly  Yes 
• Reporting of the variable selection 
process 
It is adequate if it is based on consideration 
of the clinical importance of various factors 
 
Yes 
• Statistical significance threshold The threshold of statistical significance for 
inclusion or deletion of variables (e.g. in 
stepwise forward or backward regression) 
should be reported  
 
Yes  
• Conformity to linear gradient An attempt should be made to detect this 
problem, e.g. by comparison of the observed 
and the predicted values for the outcome 
over the ordinal zones or by an alternative 
analysis using cross-stratification 
 
Yes 
How well did the overall model work? 
 
  
• Testing for goodness-of-fit The accuracy with which the regression 
model describes the data should be assessed 
 
Yes 
How important was each of the 
independent variable? 
 
  
• Unit of measurement  The change in dependent variable associated 
with a unit change in the independent 
variable should be reported 
 
Yes 
• Coding of variables  A description of variables if they were on an 
interval, ordinal or binary scale should be 
provided 
 
Yes 
• Testing for interactions when the impact of one variable is dependent 
on the level of another variable, interactions 
between independent variables should be 
examined 
  
Yes 
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The results for endometrial thickness measurement by ultrasound scan and hysteroscopy should 
however, be interpreted in the context of hypothesis generation. This is because the approach in this 
paper was limited to assessing the feasibility of developing an analytical strategy using standard 
software. The results from this data set of 248 women with abnormal uterine bleeding should not 
therefore be seen as assessing diagnostic value of the various tests. In addition, because of relative 
paucity of outcome events, the estimates of accuracy may be unstable, a situation in which exact 
methods for performing logistic regression may be more appropriate (Mehta 1995). 
 
7.4.3 Relation to other studies considering differences in quality and results 
There is no other similar study to use for discussion. 
  
7.4.4 Practical implications for clinicians  
There are no practical implications as this is a feasibility or pilot analysis. 
 
 
7.4.5 Implications on research  
• The findings of this chapter require confirmation in a large study. 
• Diagnostic evaluation should consider multivariable analysis to evaluate combination of 
tests. 
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CHAPTER 8 
 
DISCUSSION AND CONCLUSIONS 
 
The proposed structure by Docherty and Smith (Docherty, Smith 1999) for the discussion of 
scientific papers that was used in each chapter, will be followed in this chapter as well in the 
following order:   
• Statement of principal findings  
• Appraisal of quality of the study: Strengths and weaknesses of the study  
• Relation to other studies considering differences in quality and results 
• Meaning of the study: possible mechanisms and implications for clinicians or policymakers  
• Unanswered questions and future research  
 
8.1 The principle findings of this thesis: (Table 8.1)  
1. Hysteroscopy is accurate in ruling in endometrial cancer and hyperplasia. (See 8.3 for the 
clinical implications).  
2. Ultrasound is accurate in ruling out endometrial cancer and hyperplasia. (See 8.3 for the 
clinical implications). 
3. Insufficient sample on outpatient endometrial biopsy may be considered a substitute to the 
absence of pathology provided the hysteroscopic and sonographic endometrial assessment is 
consistent with endometrial atrophy. (See 8.3 for the clinical implications). 
4. The rate of hyperplasia in the polyps group is approximately double that in the non-polyp 
group while the cancer rate was no different. (See 8.3 for the clinical implications). 
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5. Among the various risk factors associated with endometrial polyps, tamoxifen is associated 
with endometrial polyps but hormone replacement therapy is not. (See 8.3 for the clinical 
implications). 
6. The true clinical value of a test lies in the added information over and above what was 
already known from the history and examination. It is feasible to develop a stepwise 
multivariable analytic approach to explore the added value of tests (hysteroscopy or 
ultrasonography) over and above history when predicting endometrial hyperplasia or cancer. 
This analytic strategy needs to be applied in larger datasets to draw clinical conclusions. 
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Table 8.1: Summary of the thesis results 
 
Chapter 2 Accuracy of hysteroscopy in  
diagnosing endometrial  
hyperplasia /cancer 
Estimate of 
Accuracy/Association 
Change in Probability:  
Pre-test →Post test 
 
 • Negative hysteroscopy LR= 0.7  (Premen)   3.0%→2.1% 
 •    
   (Postmen) 12.5%→9.1% 
    
 • Positive hysteroscopy LR=51.1 (Premen)   3.0%→61.2% 
   (Postmen) 12.5%→87.9%         
    
Chapter 3 Accuracy of ultrasound scan in 
diagnosing endometrial 
hyperplasia /cancer 
 Change in Probability:  
Pre-test →Post test 
 • ET<4mm LR= 0.14 15%→2.4%  
 • ET>9mm LR =3.3 15%→36.8% 
    
Chapter 4 Factors associated with Insufficient 
endometrial sampling 
 Statistical Significance 
 • Ultrasonographic  ET>5mm OR= 0.19 P value=0.001 
 • Hysteroscopic endometrial 
atrophy 
OR= 4.79 P value=0.04 
     
Chapter 5 
 
Pathology in endometrial polyps 
 
 
 
Rates in polyps  
vs non polyps 
 • Hyperplasia OR= 2.1  6/62  (9.7%) vs 9/186 (4.8%) 
 • Cancer   OR= 1.5  3/36 (4.8%) vs 6/186 (3.2%) 
    
Chapter 6 
 
Factors associated with 
endometrial polyps 
 
 
Statistical Significance 
 
 • HRT  OR= 1.48 P value=0.32 
 • Tamoxifen OR= 11.21 P value=0.0009 
    
Chapter 7 Multivariable analysis  Statistical Significance 
 Clinical history +   
Hysteroscopy (suspicious vs normal) 
ROC area= 0.81 
  
P value=0.008 for 
improvement  
 Clinical history +                     
Ultrasound Scan (5mm cut-off) 
ROC area= 0.82 P value=0.02 for  
improvement         
 
LR:   Likelihood Ratio 
Premen:  premenopausal 
Postmen:  postmenopausal 
ET:   Endometrial thickness  
OR:   Odds Ratio 
ROC:  Receiver- Operating Characteristic  
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8.2 Appraisal of quality of the study 
The strength of the studies presented in this thesis and the credibility of their findings depend on the 
strength of the methodology. This is made clear by adhering to the checklist proposed by the 
STARD group (Standards for Reporting of Diagnostic Accuracy): the objective of which is to 
improve the quality of reporting of studies on diagnostic accuracy allowing the detection of the 
potential for bias in the study and to evaluate the generalisability of the results. Most of the criteria 
required for a high quality diagnostic test study were fulfilled by this thesis.  
There were independent assessments of the test and the gold standard. The gold standard histology 
was performed on all patients regardless of hysteroscopic findings. There was an adequate spectrum 
of patients both at low and at high risk of premalignant/malignant lesions. In addition, meaningful 
measures of diagnostic accuracy have been used to readily enable the reader to assess how useful 
the test might be in practice.  
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Table 8.2: Application of STARD checklist to the study reported in this thesis 
 
Section and topic Description of the criteria 
Compliance 
in the thesis 
METHODS 
Participants:  
                    Study population 
                    Setting/ Location  
                    Recruitment:  
 
Based on presenting symptoms, the participants had received the index test(s) and the reference standard? 
 
Yes 
                     Participant sampling: Consecutive series of patients defined by selection criteria Yes 
                     Data collection: Participants identified and data collected before the index test(s) and reference standards were performed 
(prospective study) 
Yes 
Reference standard  and its rationale Yes 
Test methods 
 
Technical specification of Given material and methods Yes 
 Definition and rationale for the units, cut-offs and/or categories of the results of the index test(s) and the 
reference standard 
Yes 
 The number, training and expertise of the persons (a) executing and (b) reading the index test(s)  
and the reference standard 
Yes 
 Methods for calculating measures of diagnostic accuracy or making comparisons, the statistical methods 
used to quantify uncertainty (e.g. 95% CI) and methods for calculating test reproducibility 
Yes 
RESULTS 
Participants 
 
When study was done, including beginning and ending dates of recruitment 
 
Yes 
 Clinical and demographic characteristics (e.g. age, sex, spectrum of presenting symptom(s), co morbidity, 
current treatment(s), recruitment centre) 
Yes 
Test results A cross tabulation of the results of the index test(s) by the results of the reference standard;  
for continuous results, the distribution of the test results by the results of the reference standard 
 
Indeterminate results, missing responses and  outliers of index test(s) stratified by reference standard result 
and how they were handled  
Yes 
 
 
Yes 
 
Estimation Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% CI)  
 
Estimates of variability of diagnostic accuracy between subgroups of participants (Post vs premenopausal) 
 
Yes  
 
Yes 
 
The methodology was fully explained. Several accuracy indices were used, including: 
• Sensitivity and specificity 
• The area under the receiver operating characteristic curve 
• And several categories of results were provided in the form of likelihood ratios, post-test 
probability of disease and Bayes’ theorem (Daya 1996).  
 
The evidence generated in this thesis, and presented in section 8.3, is graded using the scheme 
below for classification of evidence levels for primary research on diagnostic accuracy (Khan 
2001). (Table 8.3). 
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Table 8.3: Classification of level of evidence for primary research on diagnostic accuracy  
Level of 
Evidence 
Description  
Ia Independent, blind comparison with reference standard among an appropriate 
population of consecutive patients 
Ib An independent, blind comparison with reference standard among an appropriate 
population of non-consecutive patients or confined to a narrow population of study 
patient. 
IIa An independent, non-blind comparison with reference standard among an appropriate 
population of consecutive patients 
IIb An independent, non-blind comparison with reference standard among an appropriate 
population of non-consecutive patients or confined to a narrow population of study 
patients. 
III An independent, blind comparison among an appropriate population of patients, but 
reference standard not applied to all study patients 
IV Reference standard not applied independently or expert opinion with no explicit critical 
appraisal, based on physiology, bench research or first principles 
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However the weaknesses of the thesis are: 
Firstly, regarding the accuracy of the index text (Ultrasonography), the scan studies were performed 
by the same clinician who performed the hysteroscopy. Blindness to the result of the ultrasound 
scan was therefore not possible. Because of the small sample of participants who had the ultrasound 
scan study, additional data from another minimal access unit were incorporated to make the analysis 
more meaningful. This fact may be considered as one of the study’s strengths as it uses multicentre 
data. 
 
And secondly, one has to be careful in interpreting the findings since the study population was a 
selected group of women who were referred to the special clinic for investigation of abnormal 
uterine bleeding. This means that the generalization of our results is limited to symptomatic women. 
Also, as the sample was small, further work is needed on larger numbers taking into consideration 
the sample size required to achieve an agreed power of the test. 
 
8.3 Practical implications for clinicians  
The findings of this thesis, in my judgement, lead to the following practical recommendations:  
• Firstly: hysteroscopy is highly accurate and thereby clinically useful, in diagnosing 
endometrial cancer in women with abnormal uterine bleeding, however the diagnosis of 
malignancy should continue to be positively confirmed on histology because of the major 
surgical treatment intervention it carries with. Although this conclusion might mean that 
there has been no change in clinical practice, this is a primary diagnostic test accuracy study 
whereby abnormal hysteroscopy was found to be accurate.    
Secondly: endometrial sampling should be performed with negative hysteroscopy, as 
negative hysteroscopy is not conclusive for excluding malignancy.    
         (Evidence level Ia) 
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• Endometrial sampling may safely be skipped in women with postmenopausal bleeding, if 
the sonographic endometrial thickness is <4.0mm. This became the policy in both settings 
(MAST and GMAU centres) as a result of this study allowing to discharge these women 
without further invasive intervention (i.e. endometrial sampling or hysteroscopy).  
         (Evidence level Ia) 
• In postmenopausal bleeding, it is safe to disregard insufficient endometrial sample and 
consider it benign if sonographic endometrial thickness and hysteroscopy are normal. And 
yes we should be confident to reassure and discharge such a patient without the need to 
expose her to further investigation which conventionally means inpatient dilatation and 
curettage. This policy became the standard practice in the One-stop clinic as a result of this 
study.          
(Evidence level Ia) 
• As this study concluded that the rate of hyperplasia in the polyps group is approximately 
double that in the non-polyp group, the clinical implication recommends that the detection 
of polyps should lead to their removal followed by histological assessment as there is some 
evidence indicates that the risk of recurrence of endometrial polyp is expected in the 
presence of an abnormal proliferative activity or hyperplasia both in the endometrial polyp 
and the surrounding endometrium (Bouda J Jr 2000). However one can be reassured that the 
risk of cancer is not increased in the polyps group. 
          (Evidence level Ia) 
• There are numerous recognized reasons for long-term non-compliant use of HRT; but the 
risk of HRT inducing endometrial polyps should not be one of these. It should be always 
remembered that tamoxifen treatment is a significant risk factor associated with endometrial 
polyps. Therefore women on tamoxifen therapy who present with abnormal uterine bleeding 
need prompt investigation.        (Evidence level Ia)  
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Based on the principles discussed above the following is a flow chart on how to manage women 
with abnormal uterine bleeding:  
 
Flow Chart: Management of women with abnormal uterine bleeding 
 
 
 
 
 
 
 
< 4 mm > 4 mm 
Outpatient hysteroscopy and 
endometrial sampling 
No need for endometrial 
sampling 
Insufficient 
sampling 
Sufficient 
sampling 
Further 
management 
depends on 
the pathology 
Risk factors 
• Older age 
• non-users of  HRT  
• Irregular ET 
• Fluid in the cavity 
• abnormal blood flow 
 
No Yes 
Endometrial thickness on ultrasound scan 
Hysteroscopic 
evidence of 
endometrial 
atrophy 
No further action, Discharge 
Reinvestigate if bleeding recurs
Yes No 
Inpatient hysteroscopy and 
endometrial sampling 
May need 
endometrial sampling 
Abnormal Uterine Bleeding 
Negative cervical smear, normal cervix and vagina on speculum examination 
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Implications on research 
This thesis, in my view, has the following recommendations for future research:  
• To determine the contribution of various tests used in women with abnormal uterine 
bleeding, further studies using larger data sets should be carried out using the analytical 
technique (stepwise analysis) outlined in chapter 7.  
• The effectiveness and cost- effectiveness of the available diagnostic tools (hysteroscopy 
/ultrasound /biopsy) are required using modeling. 
• The management of polyps requires randomised trials to address the effectiveness of various 
methods of treatment. 
• Based on the methodology shown in this feasibility study, systematic reviews using 
Individual Patients Data of relevant or large primary studies are needed to evaluate the 
accuracy of combinations of tests used in the ambulatory assessment of menstrual disorders  
• Guideline or national consensus on how to investigate menstrual disorders/abnormal uterine 
bleeding is needed. Such a guideline was recently published in Scotland (the Scottish 
Intercollegiate Guideline Network 2002). The guidelines are helpful, not only to guide 
practice, but to establish the current state of knowledge and can be updated as more research 
information becomes available.  
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APPENDIX 1   
 
Letters from the Chief of Research and Development Committee and from the Clinical 
Governance Manager regarding the ethical approval 
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APPENDIX 2 
Clarification about author’s contribution to chapter 3  
 
The clinical work presented in this thesis through all chapters, was carried out at Birmingham 
women’s hospital by the effort of the author; this included the 248 patients/data from the One-stop 
clinic.  
Chapter 3, however, presented data from the above cohort as well as data from another centre: the 
Gynaecology Minimal Access Unit, Ninewells Hospital, Dundee. This included 52 patients/data. 
This chapter appeared as a peer review article whereby combined data from both centres were 
presented. To keep the consistency, it is been decided to keep Dundee’s data when writing this 
thesis.  
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